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LEGAL AND ETHICAL IMPLICATIONS
OF EPIGENETICS
Mark A. Rothstein, I Yu Cai,tt and Gary E. Marchant ttt
Abstract: Epigenetics is one of the most scientifically important,
and legally and ethically significant, cutting-edge subjects of scientific
discovery. Epigenetics link environmental and genetic influences on
the traits and characteristics of an individual, and new discoveries
reveal that a large range of environmental, dietary, behavioral, and
medical experiences can significantly affect the future development
and health of an individual and their offspring. This article describes
and analyzes the ethical and legal implications of these new scientific
findings.
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"At the heart of this new field [of epigenetics] is a simple but
contentious idea - that genes have a 'memory.' That the
lives of your grandparents - the air they breathed, the food
they ate, even the things they saw - can directly affect you,
decades later, despite your never experiencing these things
yourself." BBC, Ghost in Your Genes.
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I. INTRODUCTION
Following completion of the sequencing of the human genome in
2003, the functional analysis of the human genetic code seemed to be
a relatively straightforward task. In fact, notwithstanding the enor-
mous progress in understanding the genetic basis of diseases and other
traits made possible by the Human Genome Project, full understand-
ing of human genetic processes has turned out to be far more complex
than initially expected. Perhaps the most important of these com-
plexities is epigenetics, which plays a major role in the expression of
human genetic traits. From cancer to environmental toxicity to ma-
ternal behavioral effects to in vitro fertilization risks, epigenetic ef-
fects play an important, previously under-appreciated role in the inter-
action of nature and nurture to determine human traits.
Epigenetic changes are alterations in the chemical modification of
DNA that do not involve modifying the actual DNA sequence, which
is the genetic information coding for the various inherited traits and
predispositions in humans and other organisms. Although epigenetic
effects do not change the genetic code per se, they leave "marks" on
the DNA sequence, which in turn affect whether, when, and how spe-
cific segments of the genetic code are turned on or "expressed." Ac-
cordingly, the genetic code has been compared to the hardware of a
computer, whereas epigenetic information has been compared to
computer software that controls the operation of the hardware.' Fur-
ther, the factors that affect the epigenetic information may be analo-
gized as parameters for operating the software.
There is growing awareness of the importance of epigenetics from
both a health and policy perspective.2 This is due in large part to the
realization that the epigenome is highly sensitive and responsive to
environmental influences, including toxic exposures, dietary factors,
and behavioral impacts. While the nature and importance of at least
some epigenetic changes are well-established, many of the implica-
1 Dana C. Dolinoy, Jennifer R. Weidman & Randy L. Jirtle, Epigenetic
Gene Regulation: Linking Early Developmental Environment to Adult Disease, 23
REPRODUCTIVE TOxICOLOGY 297, 298 (2007).
2 As one leading scientific journal recently observed, "[w]e have recently
witnessed an explosion of research efforts, meetings and symposia, international
initiatives, internet resources, commercial enterprises, and even a recent textbook
dedicated to epigenetics." Aaron D. Goldberg, C. David Allis & Emily Bernstein,
Epigenetics: A Landscape Takes Shape, 128 CELL 635, 635 (2007). The National
Institutes of Health selected epigenetics as one of its two top-priority "Roadmap
Initiatives" for 2008 and has committed $190 million in funding over the next five
years. Elizabeth Pennisi, Are Epigeneticists Ready for Big Science?, 319 SCIENCE
1177 (2008).
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tions and mechanisms of epigenetics remain uncertain or speculative.
Although the term epigenetics has been used for decades, most of the
progress and insights in understanding epigenetics has occurred in the
past decade, and much remains to be understood. Several major sci-
entific undertakings have recently focused efforts on epigenetic re-
search, and significant new developments in this field are occurring
on a continual basis. It is clear that epigenetics is an enormously im-
portant and generally under-appreciated mediator between the envi-
ronment and genetics, and epigenetics is already presenting important
regulatory, legal, and ethical issues.
This article provides an initial exploration of the legal and ethical
implications of the rapidly emerging science of epigenetics. Part II
defines epigenetics, summarizes the characteristics of epigenetic
mechanisms, and describes the current state of research in this emerg-
ing field. Some examples of effects that can result from aberrations in
epigenetics are also discussed. Part III explores legal issues raised by
epigenetic data, including both regulatory and litigation applications.
Part IV addresses the ethical implications of epigenetics. Part V con-
cludes by noting the conceptual and practical challenges in societal
responses to epigenetics.
II. BACKGROUND
A. Description of Epigenetics
The term "epigenetics" was first introduced in 1942 by Conrad
Waddington to describe the interactions of genes with their environ-
ment, which bring the phenotype into being.3 Today, epigenetics re-
fers to modifications of the genome that do not involve a change of
DNA sequence (i.e., the A's, C's, G's and T's that code information
in DNA).4 Until recently, most genetic variation was believed to be
caused by mutations that change the DNA sequence, thus resulting in
altered gene products with different properties affecting the develop-
ment of phenotypic traits, such as eye color, metabolism, and disease
3 Conrad H. Waddington, The Epigenotype, 1 ENDEAvOuR 18, 18 (1942).
4 EPIGENETIC MECHANISMS OF GENE REGULATION 1 (Vincenzo E. A. Russo,
Robert A. Martienssen & Arthur D. Riggs eds., 1996). DNA consists of a sequence
of four different DNA bases or "nucleotides" that consist of adenine (A), thymine (T),
guanine (G), and cytosine (C). The order of these nucleotides in a specific functional
stretch of DNA called a gene conveys the informational content of DNA. In the DNA
double helix, which consists of two parallel strands of DNA bound together in a
coiled spiral, C's always bind with G's on the complementary strand, and A's bind
with T's.
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susceptibility.5 While epigenetic changes can result in changes in the
expression of these same traits, they do so not by changing the form or
function of gene products, but by altering the timing and quantity of
their production in tissues at key points in time.6 Changes in deter-
mining which genes are expressed and their degree of expression can
have dramatic effects on the development and characteristics of an
organism.
Some epigenetic changes involve chemical alterations to the DNA
molecule itself, most commonly the addition of a methyl group to
cytosine bases (the "C's") to form methyl-cytosine,7 which makes the
DNA molecule in that region less likely to be expressed. This binding
predominantly occurs at sites where a C precedes a guanine ("G")
base to form what is referred to as a CpG site.8 In somatic cells,
approximately 70 percent of the over 28 million CpG units in the
human genome are normally methylated, helping to suppress
expression of many genes.9 CpG sites often are clustered upstream of
many mammalian genes to form CpG islands. These upstream
regions are often the "promoter" region of a gene, where the binding
of a specific molecule (the "promoter protein") that recognizes the
promoter sequence will cause the gene to be expressed.
When the CpG islands are relatively unmethylated, that region of
the chromosome is in an "open" configuration that permits increased
accessibility to the gene promoter.'0 In contrast, binding of a methyl
5 See BENJAMIN A. PIERCE, GENETICS: A CONCEPTUAL APPROACH 433-68
(2d ed. 2006) (explaining transcription and gene regulation, mutation and gene prod-
ucts).
6 Wolf Reik, Stability and Flexibility of Epigenetic Gene Regulation in
Mammalian Development, 447 NATuRE 425, 425 (2007).
7 Methylation of cytosine (C) nucleotide bases may only occur where the C
is followed by a guanine (G) base, in what is called a CpG dinucleotide in vertebrates.
Methylation of C also occurs to CpNG sites in some organisms. Adrian Bird, DNA
Methylation Patterns and Epigenetic Memory, 16 GENES & DEV. 6, 9 (2002).
8 The "p" refers to the phosphorous group that helps bind together adjacent
base pairs in the DNA sequence.
9 Romulo M. Brena & Joseph F. Costello, Genome-Epigenome Interactions
in Cancer, 16 HUM. MOLECULAR GENETICS R96, R96 (2007); Andrew P. Feinberg &
Benjamin Tycko, The History of Cancer Epigenetics, 4 NATuRE REv. GENETICS 143,
143 (2004); DNA methylation of CG dinucleotides is one of the mechanisms of
epigenetic regulation. William Coleman & Ashley Riverbark, Quantitative DNA
Methylation Analysis: the Promise of High-Throughput Epigenomic Diagnostic
Testing in Human Neoplastic Disease, 8 J. MOLECULAR DIAGNOSTICS 152, 153-4
(2006) (70-80% of the CGs in the entire genome are methylated to maintain chromo-
somal stability. The remaining 20-30% of CGs are clustered, many of which are
associated with genes).
10 See Jessica E. Sutherland & Max Costa, Epigenetics and the Environment,
983 ANNALS N.Y. ACAD. SCI. 151, 152 (2003).
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group to a cytosine base makes the DNA strand less available to be
expressed. If enough of the cytosine bases in a CpG island upstream
of a gene are methylated ("hypermethylation"), these epigenetic
changes will turn off the gene. There is thus an inverse relationship
between DNA methylation and gene expression.1' Methylation is
responsible for the normal suppression of many genes in somatic
cells. 12
Other epigenetic changes involve chemical alterations to the pro-
teins that bind with DNA to form chromosomes, including methyla-
tion or acetylation of histone proteins that bind with DNA and affect
the higher-order structure of chromosomes and the nucleus.' 3 For
example, the acetylation of histone proteins signals an open configura-
tion of the chromosomal region that promotes expression, whereas
deacetylation causes the chromosome to become more compacted and
inactive.' 4 The third and most recently discovered type of epigenetic
effect is RNA interference, which involves RNA molecules produced
from DNA binding back to the DNA at specific sites to turn off gene
expression.15 Although the various types of epigenetic changes have
generally been studied separately until recently, "[i]t is becoming
clear that significant crosstalk exists between different epigenetic
pathways.' 6 Each epigenetic change is referred to as a "mark," and
the total set of epigenetic marks in an organism is referred to as the
epigenome.
An important aspect of epigenetic changes is that they are durable,
have a propensity to spread, and can even be transmitted from one
generation to the next. Some epigenetic alterations, in particular DNA
methylation changes, are inheritable both from a progenitor cell to its
progeny cells through the process of mitosis (cell division), and from
a progenitor organism to its progeny organisms through the process of
meiosis (sexual reproduction).' 7 Thus, for example, when the DNA
" Rebecca E. Watson & Jay I. Goodman, Epigenetics and DNA Methylation
Come ofAge in Toxicology, 67 ToxiCOL. SCIENCES 11, 11-12 (2002).
12 Brena & Costello, supra note 9, at R96; Feinberg & Tycko, supra note 9,
at 146.
13 Adrian Bird, Perceptions of Epigenetics, 447 NATURE 396, 397 (2007).
Acetylation is chemically adding an acetyl group (CH 3-CO-) to the histone protein.
14 Moshe Szyf, The Dynamic Epigenome and its Implications in Toxicology,
100 J. ToxiCOLOGICAL Sci. 7, 9 (2007). Deacetylation is removing an acetyl group
(CH 3-CO-) from the histone protein.
15 See generally Christopher B. Schaefer et al., Epigenetic Decisions in
Mammalian Germ Cells, 316 SCIENCE 398, 398 (2007) (stating that RNA dependant
DNA methylation is a candidate mechanism for de novo DNA methylation).
16 Goldberg et al., supra note 2, at 637.
17 Paula M. Vertino et al., DNMTJ is a Component of a Multiprotein DNA
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strand copies itself when a cell divides, the methyl groups on the par-
ent DNA strand are copied onto the new daughter DNA strand. A
growing body of evidence exists in animals, plants, and humans that
epigenetic effects induced by many types of stimuli and interven-
tions-including nutrition, endocrine disrupting chemicals, maternal
care, and maternal stress-can be inherited transgenerationally and
affect subsequent generations. 
8
Another important aspect of epigenetic effects is that they are sen-
sitive to the stage of development, at which epigenetic patterns are
subject to reconfiguration or "reprogramming."' 9 The age at which an
organism is exposed to epigenetic-altering substances or behaviors is
therefore a critical factor affecting the consequences of such exposure.
Exposures to developing fetuses at the gestation stage and newborn
offspring involve the most sensitive periods for many epigenetic
effects.20
B. The Roles of Epigenetic Programming in Normal Cells
Epigenetics plays several important roles in normal cells. The
primary function of epigenetic programming is to control cell differ-
entiation through differential gene expression. 2' Every somatic (i.e.,
non-gametic) cell in the human body has essentially the same genetic
material.22 Yet, different cell types, whether skin cells, muscle cells,
Replication Complex, 1 CELL CYCLE 416, 416 (2002). Unlike DNA methylation
changes, which are heritable, no evidence or known mechanism exist for transgenera-
tional replication of other epigenetic changes, such as histone modifications. Mark
Ptashne, On the Use of the Word 'Epigenetic,' 17 CURRENT BIOLOGY R233, R233
(2007).
18 Catherine Gallou-Kabani et al., Nutri-epigenomics: Lifelong Remodelling
of our Epigenomes by Nutritional and Metabolic Factors and Beyond, 45 CLINICAL
CHEMISTRY & LABORATORY MED. 321, 321, 323 (2007).
19 See Jennifer Brennan & Blanche Capel, One Tissue, Two Fates: Molecular
Genetic Events that Underlie Testis Versus Ovary Development, 5 NATURE REV.
GENETICS 509, 510 (2004) (the stage of sex determination starts during the seventh
week of pregnancy, when the differentiation of the single primordial-gonad to a testis
or an ovary determines the sex of the embryo); Dolinoy et al., supra note 1, at 298
("[The human] epigenome is particularly susceptible to deregulation during gestation,
neonatal development, puberty, and old age."); Philip Robichaud, Metaphysics and
Morality at the Boundaries of Lfe, 31 J. MED. & PHIL. 97, 100-102 (2006) (analyzing
theories that argue that the two most critical stages of epigenetic programming in
human embryonic development are gastrulation and sex determination, gastrulation
takes place around 16 days after fertilization in humans, during which cell migration
restructures drastically the embryo morphology).
20 Dolinoy et al., supra note 1, at 298.
21 Id. at 300; Szyf, supra note 14, at 9.
22 Red blood cells are an exception because these cells lack a nucleus, and
thus lack most of their genetic material. In all other types of cells, spontaneous muta-
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bone cells, or nerve cells, display markedly different properties due to
different sets of genes being turned on or off. Because different cell
types maintain their fate during cell division even though their DNA
sequences remain the same, essentially, the developmental processes
are regulated largely by epigenetic mechanisms that turn off unneeded
genes in a tissue-specific pattern.23
A second function of epigenetic programming is to control trans-
posable elements in the genome. Transposable elements or trans-
posons, sometimes referred to in the vernacular as "jumping genes,"
are DNA segments that have the capability and propensity to jump
around the genome. These sequences are very common in the human
genome (estimated to comprise up to 50 percent of the entire human
genome),24 they tend to be highly repetitive sequences, and they
probably originated from viruses or other pathogens and subsequently
became integrated into the human genome.25 While some movement
of transposable elements around the genome can generate new genetic
variation and flexibility, such movement can be damaging by integrat-
ing and disrupting other important genes, potentially resulting in mu-
tation and cancer-generating changes. Epigenetic programming often
silences these disruptive sequences by making the surrounding chro-
matin more compact, thereby inhibiting the replication and transposi-
tion of transposable elements.26
A third epigenetic function in normal cells is a process known as
"imprinting." 27 Usually, both copies of a gene in the human genome
are expressed, but some genes are subject to imprinting, which
selectively "turns off' either the copy of the gene received from the
mother or the copy received from the father. Several hundred human
genes, or approximately one percent of human genes, are believed to
be subject to this imprinting phenomenon, which involves DNA
tions may arise in individual cells during cell replication.
3 Andrew P. Feinberg, Phenotypic Plasticity and the Epigenetics of Human
Disease, 447 NATURE 433, 437 (2007).
24 R. Keith Slotkin & Robert Martienssen, Transposable Elements and the
Epigenetic Regulation of the Genome, 8 NATURE REV. GENETICS 272, 272 (2007).
25 See Timothy H. Bestor, Cytosine Methylation Mediates Sexual Conflict, 19
TRENDS GENETICS 185, 185 (2003); Robert A. Waterland & Randy L. Jirtle, Early
Nutrition, Epigenetic Changes at Transposons and Imprinted Genes, and Enhanced
Susceptibility to Adult Chronic Diseases, 20 NuTRITION 63, 65 (2004).
26 Randy L. Jirtle & Michael K. Skinner, Environmental Epigenomics and
Disease Susceptibility, 8 NATURE REV. GENETICS 253, 253 (2007); see, Slotkin &
Martienssen, supra note 24, at 272 ("[T]he genome has evolved epigenetic 'defense'
mechanisms to suppress [transposable elements] activity.").
27 See sources cited supra notes 20-21.
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methylation. 8 The leading theory for explaining gene imprinting is
that it represents a battle between the sexes, known as the parental
conflict hypothesis.29 According to this hypothesis, genes that cause a
mother to devote more energy and resources to its developing
offspring tend to favor the reproductive success of the father's genes
(in the form of the embryo) over the mother's well-being, and for such
genes the paternal version tends to be expressed while the maternal
version is silenced in the offspring.30 Conversely, genes that do not
sacrifice the mother's health for the benefit of the offspring tend to be
maternally expressed with the paternal contribution silenced. One
implication of this "battle of the sexes" played out through epigenetic
imprinting is that it matters from which parent you get a gene. It may
also explain why some conditions, including autism, Alzheimer's
disease, bipolar disorder, and schizophrenia, have higher risks of
being passed on to the next generation depending on whether the
mother or father has the condition.3' In addition to genes imprinted in
a parent-of-origin-specific manner,32 other genes seem to be randomly
imprinted, with up to five percent of human genes having only one or
the other copy expressed in a given tissue, resulting in yet another
epigenetic mechanism producing divergent genetic expression from
the same genotype.33
Finally, and perhaps most significantly from the perspective of
public policy and health protection, epigenetics provides a mechanism
for a developing organism, either in utero or post-natally, to assess its
environment and adjust its genetic response accordingly. The power-
ful influence that epigenetic effects can have on the expression of
genes, and thus the organism's resulting phenotype, provides a rapid
28 Zdenko Herceg & Pierre Hainaut, Genetic and Epigenetic Alterations as
Biomarkers for Cancer Detection, Diagnosis and Prognosis, 1 MOLECULAR
ONCOLOGY 26, 34 (2007); Jirtle & Skinner, supra note 26, at 255; Randy L. Jirtle &
Jennifer R. Weidman, Imprinted and More Equal, 95 Am. SCIENTIST 143, 143, 145
(2007).
29 Jirtle & Skinner, supra note 26, at 255; See Jon F. Wilkins & David Haig,
What Good is Genomic Imprinting: The Function of Parent-Specific Gene Expres-
sion, 4 NATURE REv. GENETICS 359 (2003).
30 Jirtle & Skinner, supra note 26, at 256.
31 Jirtle & Weidman, supra note 28, at 149.
32 A long-known example of such parent-of-origin phenomena, which only
recently was realized to operate by an epigenetic mechanism, is the different effect of
crossing a female horse with a male donkey to produce a mule, whereas a male horse
and female donkey will produce a "hinny." Philip Hunter, The Silence of the Genes:
Is Genemoic Imprinting the Software of Evolution or Just a Battleground for Gender
Conflict?, 8 EMBO REP. 441,441 (2007).
33 Alexander Gimelbrant et al., Widespread Monoallelic Expression on
Human Autosomes, 318 SCIENCE 1136, 1136-40 (2007).
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feedback mechanism by which an individual's environment can influ-
ence its genetically-programmed development. Such mechanisms
allow a developing organism to adjust its phenotype to its anticipated
environment, thereby increasing its fitness (provided that the envi-
ronment does not change significantly between the organism's early
developmental stages when epigenetic patterns are set and the adult
environment).34 Various factors, such as diet, lifestyle, and environ-
mental exposures, can affect the epigenetic status of human and other
organisms, helping to direct their development.35
As discussed above, the individual is particularly sensitive to
these epigenetic influences at certain early stages of development. As
one writer succinctly described this dynamic, "[t]he notion is that we
experience periods in development when our bodies are programmed
to collect information about our environment, then readjust our
growth depending on what we find.",36 This flexibility allows an indi-
vidual organism to adapt its genetic expression to the environmental
conditions it encounters in early development, without the necessity of
permanent changes to the genome that would limit the flexibility of
future generations that may experience very different conditions.37 As
succinctly summarized by one leading epigenetics researcher, epi-
genetics allows an organism to rapidly "respond to the environment
without having to change its hardware.,
38
By this mechanism, environmental factors produce changes in
gene expression and resulting genetic characteristics over an individ-
ual's lifetime, rekindling the early nineteenth century concept of the
heritability of "acquired characteristics" attributed to
Jean-Baptiste Lamarck. 39 By providing a mechanism by which envi-
ronmental factors can influence the expression of genes, epigenetics
40
acts as a mediator between the environment and the genome.
As discussed further below, when certain environmental factors
affect a critical epigenetic control in the rapidly developing organs, it
34 Peter D. Gluckman et al., Metabolic Plasticity During Mammalian Devel-
opment is Directionally Dependent on Early Nutritional Status, 104. PROC. NAT'L
ACAD. Sc. 12796, 12796 (2007).
35 Jirtle & Skinner, supra note 26, at 253.
36 Rachael Moeller Gorman, The New Heredity, PROTOMAG , Fall 2007, at
39, 39, available at http://protomag.com/issues/2007_fall/pdfs/heredity.pdf.
37 Reinhard St6ger, The Thrifty Epigenotype: An Acquired and Heritable
Predisposition for Obesity and Diabetes?, 30 BIoESSAYS 156, 159-60 (2008).
38 Leslie A. Pray, Epigenetics: Genome, Meet Your Environment, SCIENTIST,
July 5, 2004, at 14, 14 (quoting Randy Jirtle).
39 See RiCHARD W. BURKHARDT, JR., THE SPIRIT OF SYSTEM: LAMARcK AND
EVOLUTIONARY BIOLOGY 1-2 (1977).
40 See St6ger, supra note 37, at 159.
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often leads to diseases in the person exposed.4' Some epigenetic
changes leading to cancers and other diseases have been found to be
transgenerational with nearly 100 percent penetrance, in that the al-
tered epigenetic pattern can be transmitted to subsequent generations
effectively without physically being exposed to the original trigger of
the epigenetic change.42
C. Examples of Abnormal Epigenetic Effects
Although epigenetic mechanisms are important for normal
development, the disruption of epigenetic processes can lead to
detrimental consequences. As one recent review noted, "[j]ust as
epigenetic change is at the heart of normal development, so also do
disruptions in epigenetic modifications disturb normal developmental
programs. 43 Some prominent examples of epigenetic aberrations that
can adversely affect human health and welfare are summarized below.
1. Cancer
It is now widely accepted that epigenetics plays a key role in
many cancers, 44 and indeed DNA methylation has even been referred
to as the "hallmark of cancer., 45  Two types of abnormal DNA
methylation patterns are observed in virtually all human cancers,
including colon, breast, prostate, and lung tumors.46 First, genome-
wide hypomethylation, or the loss of methylation, has been
demonstrated in almost all human tumor types.47  This loss of
methylation could result in the activation of normally suppressed
oncogenes, which are genes that promote tumor formation, thereby
increasing the risk of cancer.48 The degree of hypomethylation of
41 Matthew D. Anway et al., Epigenetic Transgenerational Actions of
Endocrine Disruptors and Male Fertility, 308 Sci. 1466, 1466 (2005); Marcus E.
Pembrey et al., Sex-Specific, Male-Line Transgenerational Responses in Humans, 14
EuR. J. HuM. GENETICS 159, 159-66 (2006) (demonstrating that an inherited disease
phenotype in humans that is potentially induced by an epigenetic phenomenon).
42 Dolinoy et al., supra note 1, at 298; Anway et al., supra note 41, at 1466.
43 Andrew P. Feinberg, Epigenetics at the Epicenter of Modern Medicine,
299 JAMA 1345, 1348 (2008).
44 Peter A. Jones & Stephen B. Baylin, The Epigenomics of Cancer, 128
CELL 683 passim (2007).
45 Szyf, supra note 14, at 15.
46 Stephen B. Baylin et al., Alterations in DNA Methylation: A Fundamental
Aspect of Neoplasia, 72 ADVANCES CANCER RES. 141, 155 (1998); Herceg & Hainaut,
supra note 28, at 32-33.
47 Feinberg & Tycko, supra note 9, at 143; Manel Esteller, Molecular Ori-
gins of Cancer: Epigenetics in Cancer, 358 NEw ENG. J. MED. 1148, 1149-50 (2008).
48 Feinberg & Tycko, supra note 9, at 143.
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many tumors is related to the aggressiveness of the tumor: as the
tumor becomes progressively demethylated it becomes more
dangerous and invasive in form .4 9  The overall reduction of
methylation in cancerous cells is accompanied by increases in
methylation (hypermethylation) at specific sites in the genome.
Second, more localized hypermethylation of the promoter regions of
tumor suppression genes that normally help the cell stave off tumor
formation results in reduced expression of those genes, and hence
increased risk of tumor formation.50 In mice, experimental data
directly demonstrate that this global hypomethylation and localized
hypermethylation can cause cancer. 51
Another epigenetic mechanism of cancer causation is loss of
imprinting. Aberrant activation of the normally silent copy of an
imprinted growth-promoting gene, or aberrant silencing of the
normally expressed copy of an imprinted tumor suppressor gene, can
result in cancer formation. 52 For example, in Beckwith-Wiedemann
syndrome,53 loss of imprinting of two neighboring stretches of the
DNA on the maternal chromosome that are normally imprinted
disrupts the normal function of the cells in responding to internal or
external environmental cues.54
2. Adult Onset Diseases
Scientists have established that DNA methylation patterns change
throughout the stages of human development, and changes are the
most drastic during embryogenesis. Strong evidence supports the
notion that predisposition to various types of diseases that do not
manifest until later in life may be encoded epigenetically at early de-
velopmental stages.5 5 This theory, sometimes referred to as the "early
49 Esteller, supra note 47, at 1149.
50 Sutherland & Costa, supra note 10, at 152.
51 Andrew P. Feinberg, Genomic Imprinting and Gene Activation in Cancer,
4 NATURE GENETICS 110, 113 (1993).
52 Id. at 112.
53 Beckwith-Wiedemann syndrome, or BWS, is a rare overgrowth genetic or
epigenetic syndrome associated with an increased risk of embryonic tumor formation,
which leads to a 20% mortality rate among newborns with BWS. See ROBBrNS &
COTRAN, PATHOLOGIC BASIS OF DISEASES 505 (Vinay Kumar, Abul Abbas, & Nelson
Fausto eds., Elsevier Saunders, 7th ed. 2003).
54 Michael R. DeBaun & Andrew P. Feinberg, IGF2, H19, p 5 7 JP2, and LIT]
and the Beckwith-Wiedemann Syndrome, in INBORN ERRORS OF DEVELOPMENT: THE
MOLECULAR BASIS OF CLINICAL DISORDERS OF MORPHOGENEsIs 758, 758-65 (Charles
J. Epstein et al. eds., 2004).
55 See Matthew D. Anway & Michael K. Skinner, Epigenetic Transgenera-
tional Actions of Endocrine Disruptors, 147 ENDOCRINOLOGY S43, S43 (2007)
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origins" or fetal basis of adult disease model,56 hypothesizes that "the
evolution of developmental plasticity, which enables an organism to
adapt to environmental signals during early life, can also increase the
risk of developing chronic diseases when there is a mismatch between
the perceived environment and that which is encountered in adult-
hood., 57 Evidence links DNA methylation to common late onset dis-
eases, such as hypertension, diabetes, obesity, schizophrenia,58 and
bipolar disorder;59 developmental disorders, such as Beckwith-
Wiedemann syndrome, Angelman syndrome, 60  Prader-
Willi syndrome; 61 and other disorders, such as Alzheimer's disease,
asthma, and coronary artery disease.62
An intriguing example of such an effect is growing evidence from
both animal and human studies that nutritional scarcity in early de-
velopment epigenetically programs individuals with a "thrifty" pheno-
type that allows them to maximize energy and growth from scarce
food resources.6 3 Once established in early development, this pheno-
type is fixed for the lifetime of the individual. However, if the indi-
vidual encounters different conditions later in life where food is more
abundant, the epigenetic programming will now mismatch with the
environment, with the result that the individual is prone to developing
(defects in the epigenome changes during these critical stages of embryonic
development are known to lead to aberrant gene expression and diseases such as
cancer); Feinberg, supra note 23, at 438.56 Dolinoy et al. supra note 1, at 298.
57 Jirtle & Skinner, supra note 26, at 253-54.
58 Jonathan Mill et al., Epigenomic Profiling Reveals DNA-Methylation
Changes Associated with Major Psychosis, 82 AM. J. HuM. GENETICS 696, 697
(2008).
59 Id.
60 Angelman Syndrome (AS), is a neurological genetic disorder due to the
abnormal imprinting on the maternal copy of chromosome 15. AS is associated with
developmental delay and mental retardation. See Raymond J. Barry et al., Behavioral
Aspects of Angelman Syndrome: A Case Control Study, 132A AM. J. MED. GENETICS
8, 8-9 (2005).
61 See Suzanne B. Cassidy et al., Prader-Willi and Angelman Syndromes:
Sister Imprinted Disorders, 97 AM. J. MED. GENETiCS 136, 136-37 (2000) (Prader-
Willi syndrome (PWS) is a complex disorder caused by the abnormal imprinting on
the paternal derived chromosome and has fifteen distinct characteristics in compari-
son to Angleman Syndrome.).
62 Myriam Fornage, Unraveling Hypertension: Epigenomics Comes of Age, 8
PHARMACOGENOMICS 125, 125 (2007); Rachel L. Miller & Shuk-mei Ho, Environ-
mental Epigenetics and Asthma: Current Concepts and Call for Studies, 177 AM. J.
RESPIRATORY & CRITICAL CARE MED. 567, 567 (2008).
63 See, e.g., St6ger, supra note 37, at 159-62; Waterland & Jirtle, supra note
25, at 63.
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conditions such as obesity and Type 2 diabetes. 64 For example, a
study of 300,000 young men born before, during, and after an extreme
eight-month famine in the Netherlands during World War I1 found a
significantly higher incidence of obesity in those individuals who
were in the first two trimesters of in utero development during the
famine.65
3. Transgenerational Effects of Endocrine Disrupting Chemicals
Maternal exposure to hormone disrupting chemicals (or endocrine
disruptors), such as xenoestrogens, oestrogenic (estrogenic), and hor-
mone mimicking chemicals, may interfere with the epigenetic re-
programming of the fetal germline at key stages of early development,
resulting in transgenerational adverse effects. Perhaps the best-known
example of such effect is from diethylstilbestrol (DES), an estrogenic
pharmaceutical agent given to pregnant women from the 1940s to the
early 1970s to avoid miscarriage. DES ingestion increased the risk of
reproductive disorders and rare forms of cancer in DES daughters and
granddaughters. 66 Animal tests suggest the effects of maternal DES
exposure were transmitted through the maternal germline to offspring
via both genetic and epigenetic mechanisms.67
Although DES has been banned for several decades, other endo-
crine disruptor chemicals may operate through epigenetic mechanisms
to adversely affect human health. For example, vinclozolin, a fungi-
cide used on a number of crops such as grapes and strawberries,
induces a wide variety of adverse effects, including spermatogenic
abnormalities, male infertility, breast cancer, and kidney disease, in
animal tests, not only in the first generation but also in generations
two through four.68 These abnormalities occur at frequencies ranging
64 See St6ger, supra note 37, at 160.
65 Gian-Paolo Ravelli, Zena A. Stein & Mervyn W. Susser, Obesity in Young
Men After Famine Exposure in Utero and Early Infancy, 295 NEw ENG. J. MED. 349,
349-52 (1976).
66 Ruthann M. Giusti, Kumiko Iwamoto & Elizabeth E. Hatch, Diethylstilbe-
strol Revisited: A Review of the Long-Term Health Effects, 122 ANNALS INTERNAL
MED. 778, 778-88 (1995); June Machover Reinisch, Mary Ziemba-Davis, & Stepha-
nie A. Sanders, Hormonal Contributions to Sexually Dimorphic Behavioral Develop-
ment in Humans, 16 PSYCHONEUROENDOCRINOLOGY 213, 213-78 (1991).
67 M.M. Brouwers et al., Hypospadias: A Transgenerational Effect of Dieth-
ylstilbestrol?, 21 HUM. REPROD. 666, 666-69 (2006); Retha R. Newbold, Elizabeth
Padilla-Banks & Wendy N. Jefferson, Adverse Effects of the Model Environmental
Estrogen Diethylstilbestrol Are Transmitted to Subsequent Generations, 147
ENDOCRINOLOGY (SUPP.) 11, 15-16 (2006).
68 Anway et al., supra note 41, at 1467; Jirtle & Skinner, supra note 26, at
257-58.
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from twenty to ninety percent of individual animals in subsequent
generations, an enormously high rate that is consistent with an
epigenetic mechanism. 69 Although exposure levels in this study were
much higher than typical environmental exposures, the study is impor-
tant for demonstrating that endocrine disrupting substances can have
epigenetic effects that are passed on to several subsequent
generations.
4. Ionizing Radiation
Modem low radiation cancer therapy has led to increased patient
survival rates. However, one of the radiation treatment-related comp-
lications is the potential risk of genome instability in the progeny of
radiation-treated parents. At this time, there is no conclusive evidence
of increased risk of genetic disease in offspring of long-term survivors
of cancer.7° In animal experiments, X-ray irradiation produced trans-
generational male germline-specific epigenetic mutations, which
means: an elevated mutation rate in the reproductive cells that persists
in subsequent generations. 71 Therefore, low-dose radiation may di-
rectly affect methylation and chromatin structure. In humans, a sig-
nificant reduction of global cytosine DNA methylation and the levels
of enzymes responsible for maintaining methylation were observed in
the thymus tissue of the offspring of radiation-exposed
parents.72 Given this observation of significant damage to the
epigenetic regulation system in the offspring, it is possible that the
resulting genome destabilization may be a precursor for transgenera-
tional carcinogenesis.
7 3
5. Smoking and Air Pollution
Exposure to toxic contaminants in tobacco smoke has been found
to influence the development and health of subsequent generation(s).74
One study reported that fathers who started smoking before age eleven
69 Jirtle & Skinner, supra note 26, at 257-58.
70 Julianne Byrne et al., Genetic Disease in Offspring of Long-Term Survi-
vors of Childhood and Adolescent Cancer, 62 AM. J. HUM. GENETICS 45, 45-52
(1998).
71 Ruth Barber, et al., Elevated Mutation Rates in the Germ Line of First-
and Second-generation Offspring of Irradiated Male Mice, 99 PROC. NAT'L ACAD.
Scl. U.S. 6877,6877 (2002).
72 Igor Koturbash et al., Epigenetic Dysregulation Underlies Radiation-
induced Transgenerational Genome Instability in Vivo, 66 INT'L J. RADIATION
ONCOLOGY BIOLOGY PHYSICS 327,327-30 (2006).
13 Id. at 330.
74 Pembrey et al., supra note 41.
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have sons of heavier average weight at age nine, compared to sons
whose fathers smoked later in their life or never smoked.75 The same
study also showed that paternal smoking does not affect the weight of
daughters, but does induce sex-specific, male germ-line transgenera-
tional responses in the male offspring.76 Another study found that
grandchildren of grandmothers who smoked during the fetal period
had an increased risk of developing asthma in their first five years of
life.7 With respect to air pollution, a recent study found that exposure
of mice to diesel exhaust particles and allergens induced methylation
changes beyond what occurred with exposure only to the allergen,
suggesting that such changes may be involved in asthma etiology.
78
6. Diet
Dietary factors that affect the methylation process have also been
found to affect disease risk through epigenetic mechanisms. 79 In the
fetal development of mice, dietary supplementation with nutrients that
tend to increase methylation ("methyl donors") such as folic acid,
methionine, vitamin 1312, choline and betaine, increases DNA methyl-
ation. In addition, the phytoestrogen genistein found in soy, while
not a methyl donor, also has the effect of increasing DNA methylation
through an unknown mechanism. 81 Conversely, diets lacking me-
thionine, folate, or other methyl donors have been shown to lead to
reduction in methylation across the entire genome in rats, producing
an increase in tumor formation. 2 Another study demonstrated that
reducing the availability of methyl donors such as folate acid and
certain vitamin B compounds in the diet of adult female sheep
resulted in offspring that were heavier and fatter than normal as
75 Id.
76 ld.
77 Yu-Fen Li et al., Maternal and Grandmaternal Smoking Patterns Are
Associated with Early Childhood Asthma, 127 CHEST 1232, 1238 (2005).
78 Jinming Liu et al., Combined Inhaled Diesel Exhaust Particles and Aller-
gen Exposure Alter Methylation of T Helper Genes and IgE Production In Vivo, 102
ToxICOLOGICAL SCI. 76, 80 (2008).
79 Sharon A. Ross, Diet and DNA Methylation Interactions in Cancer Pre-
vention, 983 ANN. N.Y. ACAD. SCI. 197, 202-204 (2003) ("Epimediological, preclini-
cal, and clinical evidence suggest that diet is a significant factor in cancer prevention
and cancer risk.").
80 Robert A. Waterland et al., Maternal Methyl Supplements Increase Off-
spring DNA Methylation at Axin Fused, 44 GENESIS 401, 403 (2006).
81 Jirtle & Skinner, supra note 26, at 255.
82 Lionel A. Poirier, The Role of Methionine in Carcinogenesis in vivo, in
206 ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 269, 269-82 (Lionel A.
Poirier et al. eds., 1986).
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adults, had elevated blood pressure, and were insulin resistant.83
Excessive alcohol intake also has been shown to produce global
reductions in methylation8 4 These findings suggest the need to con-
tinually reassess both the beneficial effects and the potential risks of
many dietary supplements (e.g., folates) that could affect methylation
patterns in future generations. Postnatal abnormal nutrition, such as
caloric restriction diets, could affect gene imprinting and cause
diabetic and uterine defects.
85
The classic demonstration of epigenetic effects from diet comes
from the agouti mouse, in which the coat color and health of offspring
mice are dependent on maternal dietary methyl supplementation.
Without maternal dietary supplementation, offspring tended to have
yellow coats and obesity, and were prone to diabetes and cancer,
whereas offspring of mothers which were given methyl supplements
(including folate, L-methionine, and vitamin B12) during a critical
mid-stage of gestation tended to have agouti coats and were lean and
non-diabetic.86 Significantly, this epigenetic effect was not limited to
the first-generation offspring, but was also passed on to the second
generation, suggesting that a grandmother's diet might affect her
grandchildren's health via an epigenetic mechanism. 87
Some intriguing studies in human populations have reported
evidence of such a transgenerational effect of nutritional status on
subsequent generations. For example, in one study, the food avail-
ability for grandparents when they were 8 to 12 years old affected the
longevity of their same-sex grandchildren, with scarcity of food for
the grandparent being associated with longer life expectancy in their
grandchildren of the same gender.88
83 Kevin D. Sinclair et al., DNA Methylation, Insulin Resistance, and Blood
Pressure in Offspring Determined by Maternal Periconceptual B Vitamin and Me-
thionine Status, 104 PROC. NAT'L ACAD. SCi. 19351 (2007).
84 Sang-Woon Choi et al., Chronic Alcohol Consumption Induces Genomic
but not p53-Specific DNA Hypomethylation in Rat Colon, 129 J. NUTRITION 1945,
1945-50 (1999).
85 See Dana C. Dolinoy, Jennifer R. Weidman, Robert A. Waterland &
Randy L. Jirtle, Maternal Genistein Alters Coat Color and Protects A'y Mouse Off-
spring From Obesity by Modifying the Fetal Epigenome, 114 ENVTL. HEALTH PERSP.
567, 571 (2006).
86 Jennifer E. Cropley et al., Germ-line Epigenetic Modification of the Mur-
ine A"Y Allele by Nutritional Supplementation, 103 PRoc. NAT'L ACAD. SCI. 17, 308
(2006).
87 Craig A. Cooney, Germ Cells Carry the Epigenetic Benefits of Grand-
mother's Diet, 103 PROC. NAT'L ACAD. SC!. 17071, 17071-72 (2006).
88 Gunnar Kaati et al., Transgenerational Response to Nutrition, Early Life
Circumstances and Longevity, 15 EUR. J. HUM. GENETICS 784, 784, 786 (2007).
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7. In Vitro Fertilization
Assisted reproductive procedures may disrupt imprinted genes
during epigenetic reprogramming, especially in the presence of
adverse environmental factors. As a therapy for male infertility, in
vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI)
facilitates conception using abnormal sperm, which may contain
imprinting defects. 89 However, the IVF/ICSI process may also lead to
imprinting changes from exposure of the oocyte or developing
embryo to exogenous factors in culture media. 90 Aberrant methyla-
tion of imprinted genes due to in vitro culture of embryos has been
observed in sheep and rats.91 Although no similar effects have been
observed in human embryos, the clinical data on IVF babies has
shown a six-fold increase in the incidence of Beckwith-Wiedemann
syndrome (BWS) in couples conceiving with IVF/ICSI, as well as an
increased incidence of Angelman syndrome (AS). 92 BWS and AS are
two rare diseases related to aberrant imprinting. Like other IVF/ICSI
associated imprinting-related diseases, they are caused by maternal
aberrant hypermethylation, suggesting a defect in the oocyte or
a defect occurring during the time of fertilization and early embryo
culture in the IVF/ICSI procedure. 93 Likewise, embryonic stem cells
appear to be prone to epigenetic changes which could affect their sta-
bility and utility for therapeutic applications.
94
Cloning animals using somatic cell nuclear transfer (SCNT), or
potentially cloning humans in the future, may also involve aberrant
epigenetic programming because the newly formed embryo's first key
epigenetic period occurs shortly after fertilization, when the donor
89 Thomas M. Price, Susan K. Murphy & Edward V. Younglai, Perspectives:
The Possible Influence of Assisted Reproductive Technologies on Transgenerational
Reproductive Effects of Environmental Endocrine Disruptors, 96 TOxiCOLOGICAL SCI.
218, 218 (2007).
90 Id. at 223.
91 Id.
92 DeBaun & Feinberg, supra note 54. But see Sarah Bowdin et al., A Survey
of Assisted Reproductive Technology Births and Imprinting Disorders, 22 HuM.
REPROD. 3237 (2007) (finding a much smaller increase in these conditions in children
born after in vitro fertilization than previously reported).
93 Cf Angela Sparago et al., Mechanisms Causing Imprinting Defects in
Familial Beckwith- Wiedemann Syndrome with Wilms' Tumor, 16 HUMAN
MOLECULAR GENETICS 254, 255 (2007) (showing that Familial Beckwith-Wiedemann
Syndrome is characterized by dominant maternal transmission, loss of imprinting, and
predisposition to tumors).
94 See Madlle Pannetier & Robert Feil, Epigenetic Stability of Embryonic
Stem Cells and Developmental Potential, 25 TRENDS BIOTECHNOLOGY 556, 560
(2007).
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nucleus is being integrated into the denucleated oocyte during SCNT.
According to the FDA, "[b]ecause preimplantation reprogramming
occurs after fertilization, and in the case of nuclear transfer, after
fusion of the donor nucleus with the ooplast, it is the most immedi-
ately affected by the cloning process, and may be most directly impli-
cated in the development of clones with defects . . .The [FDA]
assumes that if clones were to pose food consumption risks, the only
mechanism by which those risks could arise would be from inappro-
priate epigenetic reprogramming, similar to those observed for other
ARTs." 95
8. Aging
Aging remains the most complex phenotype studied so far. It has
been well-documented that global methylation levels decrease in
human tissues with the aging process, 96 and it has been suggested that
reduction in methylation may be associated with a functional decline
in learning and memory with age.97 Identical twins born with
identical genotypes increasingly diverge in their epigenetic profiles as
they age, with the extent of divergence increasing as the twins got
older, had different lifestyles, or spent less of their lives together.
98
"The cause of alterations in the pattern of DNA methylation during
aging is not fully understood," but the data suggest that environmental
factors modify epigenetic patterns to create different phenotypes from
the same genotype.99 Although the mechanism of these epigenetic
changes accompanying aging remains poorly defined, it appears that
these epigenetic alterations contribute to certain aging effects, includ-
95 CENTER FOR VETERINARY MED., U.S. FOOD AND DRUG ADMIN., ANIMAL
CLONING: A RISK ASSESSMENT 8 (2008), available at
http://www.fda.gov/cvm/Documents/CloningRiskAssessment FINAL.pdf.
96 C. Fuke et al., Age Related Changes in 5-methylcytosine Content in
Human Peripheral Leukocytes and Placentas: An HPLC-Based Study, 68 ANNALS
HUM. GENETICS 196, 198-99 (2004).
97 Johannes Grdff & Isabelle M. Mansuy, Epigenetic Codes in Cognition and
Behavior, 192 BEHAVIOURAL BRAIN RES. 70, 76-77 (2008).
98 Mario F. Fraga et al., Epigenetic Differences Arise During the Lifetime of
Monozygotic Twins, 102 PROc. NAT'L. ACAD. SCIENCES 10604, 10609 (2005); Emile
Zuckerkandl & Giacomo Cavalli, Combinatorial Epigenetics, "Junk DNA," and the
Evolution of Complex Organisms, 390 GENE 232, 239 (2007) (noting that the obser-
vation of acquired epigenetic differences "attracts attention to an important potential
implication of the inferred genetic/epigenetic partnership, namely, that it likely has a
Lamarckian dimension").
99 Liang Liu et al., Aging, Cancer and Nutrition: The DNA Methylation Con-
nection, 124 MECHANISMS AGEING & DEV. 989, 992 (2003); Fraga et al., supra note
98, at 10609.
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ing genomic instability, increased risk of cancer, and development of
autoimmunity.'0
9. Maternal Behavior
There are intriguing suggestions that maternal behavior can in-
duce epigenetic changes in offspring that affect health later in life.
Perhaps the most dramatic studies are those showing that nurturing
behavior by female rats to their offspring in the first week of life af-
fected behavioral patterns in those offspring, with increased pup lick-
ing and grooming resulting in grown offspring that exhibit reduced
fearfulness and better response to stress.' 0 ' These maternal program-
ming effects have been shown to be mediated by epigenetic changes
including both DNA methylation and histone changes. 10 2 While these
behavioral effects of early developmental epigenetic programming
typically last the lifetime of the animal, subsequent studies have
shown that the epigenetic effects and their behavioral consequences
can be reversed with interventions involving dietary methyl supple-
mentation. 10 3 As one review of these data summarized, "these find-
ings indicate that early postnatal life experiences can modify behav-
iour by altering the epigenome, and that the inherent plasticity of the
epigenome potentially allows for reversal in adulthood - an important
finding in terms of possible therapeutic strategies."'
0 4
A growing body of data also suggest that maternal behavior in
humans can affect the subsequent health of children via an epigenetic
mechanism. For example, a recent study found that maternal stress,
measured as medication for depression or anxiety during the early
years of a child's life, increased the risk of asthma in those children
later in life when they reach age seven. 10 5 The authors of this study
concluded that their findings "are consistent with emerging evidence
10' Q. Lu et al., Epigenetics, Disease, and Therapeutic Interventions, 5
AGEING REs. REv. 449, 451 (2006).
101 Ian C.G. Weaver et al., Epigenetic Programming by Maternal Behavior, 7
NATURE NEuRoscIENCE 847, 847 (2004).
102 Id. at 850; Ian C.G. Weaver et al., Reversal of Maternal Programming of
Stress Responses in Adult Offspring Through Methyl Supplementation: Altering
Epigenetic Marking Later in Life, 25 J. NEUROSCIENCE 11045 (2005).
103 Weaver et al., supra note 101; Ian C.G. Weaver, M.J. Meaney & Moshe
Szyf, Maternal Care Effects on the Hippocampal Transcriptome and Anxiety-
Mediated Behaviors in the Offspring that are Reversible in Adulthood, 103 PROC.
NAT'L ACAD. Sci. 3480 (2006).
104 Jirtle & Skinner, supra note 26, at 259.
105 Anita L. Kozyrskyj et al., Continued Exposure to Maternal Distress in
Early Life Is Associated with an Increased Risk of Childhood Asthma, 177 AM. J.
RESPIRATORY & CRITICAL CARE MED. 142, 143 (2008).
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that maternal care alters stress responses in the offspring through an
epigenetic model of inheritance."
D. Unique Aspects of Epigenetic Changes
Epigenetic changes are similar to genetic mutations in that they
can both result in heritable changes in gene expression and function.
In addition, there are several unique characteristics of epigenetic
changes that differ from traditional genetic mutations, including the
following.
" Epigenetic changes tend to occur at a much higher
frequency than mutations in the DNA sequences. 10 6 For
example, toxic agents acting through a genotoxic
mechanism will usually only result in mutations in less
than 0.01 percent of offspring, 10 7 whereas epigenetic
processes often affect the majority of offspring.
* Epigenetic perturbations allow for much more rapid
evolutionary change than traditional genetic mutations.
10 8
This potential for rapid variation permits a species to
respond much more quickly to changes in environmental
conditions.
* Susceptibility to epigenetic change is highly sensitive to
the dose of relevant environmental agents, and also to the
stage of development at which exposure occurs. 109 In
particular, exposure at key stages of early development
such as gastrulation and neonatal development are
disproportionately prone to result in adverse response.
The epigenetic state of an organism has a "lifecycle,"
whereas genotype does not, remaining constant throughout
the organism's lifecycle." 0 Accordingly, "the nascent
field of 'environmental epigenomics', must consider not
only the magnitude but also the timing of exposure."'
I I
* Genetic mutations tend to be irreversible, subject to
reverse mutation only at extremely low frequencies, but
epigenetic changes are intrinsically reversible.' 12  This
106 Jones & Baylin, supra note 44, at 683.
107 Jirtle & Skinner, supra note 26, at 258.
108 See Oliver J. Rando & Kevin J. Verstrepen, Timescales of Genetic and
Epigenetic Inheritance, 128 CELL 655, 655-61 (2007).
109 Dolinoy et al., supra note 1, at 298.
10 Feinberg, supra note 43, at 1346.
"1 Dolinoy et al., supra note 1, at 298.
112 Herceg & Hainaut, supra note 28, at 36; Szyf, supra note 14, at 19.
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creates the opportunity for epigenetic interventions in the
form of drugs or diet to restore normal epigenetic status,
and suggests that diseases caused by epigenetic
aberrations may be more easily treatable and preventable
than diseases caused by more permanent genetic
mutations. 1 13
Epigenetic changes tend to be tissue-specific, and thus can
differ from one cell type to another within the same
organism. 1 14 In contrast, germ-line genetic changes are
generally stable and consistent throughout the tissues of an
individual organism. This tissue-by-tissue variability of
epigenetic alterations could have important practical
effects, such as differential effects of drugs in different
tissues. 5
* Epigenetic changes also tend to be species-specific, so a
carcinogenic or toxic response in a laboratory study using
rodents may be less predictive of a similar risk for humans
than such animal results produced by genotoxic or other
traditional toxicological mechanisms.' 16 Moreover, non-
vertebrate species used in many toxicological assays have
little or no methylation, making them inappropriate for
evaluating epigenetic effects, even though they might be
useful models for mutagenesis and other toxic effects.'
1 7
E. Questions Remaining to be Answered in Epigenetics Research
Epigenetics is an emerging field, especially as applied to humans.
Aberrant DNA methylation profiles were first identified in human
cancer about twenty-five years ago. Today, epigenetic regulation has
been shown to be prevalent in the genome, and what is now known
may only be the tip of the iceberg. From September 2006 to Septem-
ber 2007, more than 2500 articles were published in this field.18
113 Stella Marie Reamon-Buettner & Jiirgen Borlak, A New Paradigm in
Toxicology and Teratology: Altering Gene Activity in the Absence of DNA Sequence
Variation, 24 REPROD. TOXICOLOGY 20, 27 (2007).
114 Szyf, supra note 14, at 13-14.
' Id. at 8.116 Jirtle & Skinner, supra note 26, at 256.
117 Szyf, supra note 14, at 10.
118 Huidong Shi, Michael X. Wang, & Charles W. Caldwell, CpG Islands:
Their Potential as Biomarkers for Cancer, 7(5) EXPERT REv. MOLECULAR DIAGNosis
519, 520 (2007).
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Numerous studies have found that many cancers and common dis-
eases are regulated epigenetically as well as genetically.
At this point, scientists are unsure of how many substances cause
epigenetic effects; what the degree of penetrance is for inherited epi-
genetic changes; what, if any, predispositions make individuals more
susceptible to epigenetic alterations; whether tests will soon be avail-
able to identify epigenetic changes before they are manifested; and
whether causal factors can be distinguished." 19 Ultimately, the an-
swers to these questions rely on the decoding of the underlying
mechanisms of epigenetic regulation related to age, diet, lifestyle,
environmental toxicity exposure, and other unrevealed factors.
Nevertheless, the gene-specific DNA methylation correlated with can-
cers and common diseases is now being investigated for potential use
as biomarkers for molecular diagnosis, prognosis and prediction of
biological aggressiveness and clinical responsiveness of disease
treatment.
With retrospective studies of DNA methylation patterns and the
availability of screening and analytical methods, the list of methylated
genes as biomarker candidates is continuously expanding.
20
However, clinically applicable biomarkers to detect diseases are still
limited. One notable finding is that a methylation biomarker for colo-
rectal cancer has a seventy percent accuracy rate in detecting cancer in
patients. 12  At the present time, there is no FDA approved DNA
methylation-based molecular test kit for diagnostic purposes. Mean-
while, epigenetic therapies are being developed to reverse gene de-
activation due to abnormal DNA methylation. The drug 5-azacytidine
is the first FDA approved hypomethylating agent to treat myelodys-
plastic syndrome, a disease involving aberrant gene promoter hyper-
methylation events.1
22
119 See generally, Lanlan Shen et al., Integrated Genetic and Epigenetic Anal-
ysis Identifies Three Different Subclasses of Colon Cancer, 104 PROC. NAT'L ACAD.
Sci. 18654, 18654 (2007) ("[C]ertain individuals appear predisposed to aberrant...
hypermethylation ... at several tumor suppressor genes."); See Sparago et al., supra
note 93. The penetrance of these mutations is found correlated with the hypermethy-
lation of the mutant allele that causes BWS. In the study of colon cancer, it is ob-
served that some individuals appear predisposed to aberrant hypermethylation at
several tumor suppressor genes.
120 See William B. Coleman & Ashley G. Riverbark, Quantitative DNA Me-
thylation Analysis: the Promise of High-Throughput Epigenomic Diagnostic Testing
in Human Neoplastic Disease, 8 J. MOLECULAR DIAGNOsTIcs 152, 155-6 (2006).
121 Shi et al., supra note 118, at 526.
122 Id. at 520; see also, Aggerholm Anni, et al., Promoter Hypermethylation
of p1 5 1N 4 , IHICI, CDH1, and ER is Frequent in Myelodysplastic Syndrome and
Predicts Poor Prognosis in Early-stage Patients, 76(1) EUR. J. HAEMATOLOGY 23,28
(2005).
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III. LEGAL APPLICATIONS
In this section we explore the subset of legal issues most closely
related to the unique scientific characteristics of epigenetics. In par-
ticular, we consider regulation, litigation, and discrimination.
A. Regulatory Applications
1. Environmental Regulation
As awareness of the critical role of epigenetics in both normal and
abnormal cell development has grown, so too has the realization of the
potential importance of the disruption of epigenetic mechanisms as a
toxicity mechanism and an environmental regulatory priority.'
23
Many important toxic chemical hazards are now known or suspected
to act, at least in part, by epigenetic mechanisms. 124 Examples include
some endocrine disrupting chemicals such as certain pesticide and
plastic compounds,1 25 and metals such as nickel, 126 cadmium, 127 and
arsenic. 128 Most recently, relatively low-level exposures to bisphenol
A, a compound used in many plastic products, was shown to cause
epigenetic alterations in rats that may increase cancer risk.
129
A number of federal environmental regulatory statutes require
assessments for risks to human health that potentially implicate
epigenetic effects, including the Clean Air Act (CAA), 3 ° the Clean
Water Act (CWA),' 3 ' the Toxic Substances Control Act (TSCA), 132
the Comprehensive Environmental Response, Compensation and
123 Jirtle & Skinner, supra note 26, at 259.
124 Dolinoy et al., supra note 1, at 303; Watson & Goodman, supra note 11, at
12.
125 See supra notes 66-69 and accompanying text.
126 Sutherland & Costa, supra note 10, at 153-55.
127 Masufumi Takiguchi et al., Effects of Cadmium on DNA-(Cytosine-5)
Methyltransferase Activity and DNA Methylation Status during Cadmium-Induced
Cellular Transformation, 286 EXPERIMENTAL CELL RES. 355 (2003).
128 R.S. Okoji et al., Sodium Arsenite Administration via Drinking Water
Increases Genome-Wide and Ha-ras DNA Hypomethylation in Methyl-Deficient
C57BL/6J Mice, 23 CARCrNOGENESiS 777, 777-85 (2002).
129 Dana C. Dolinoy, Dale Huang & Randy L. Jirtle, Maternal Nutrient Sup-
plementation Counteracts Bisphenol A-Induced DNA Hypomethylation in Early De-
velopment, 104 PROC. NAT'L ACAD. Sci. 13056, 13056 (2007); Shuk-Mei Ho et al.,
Developmental Exposure to Estradiol and Bisphenol A Increases Susceptibility to
Prostate Carcinogenesis and Epigenetically Regulates Phosphodiesterase Type 4
Variant 4, 66 CANCER RES. 5624, 5624-32 (2006).
130 42 U.S.C. §§ 7401-7671q (2000).
13' 33 U.S.C. §§ 1251-1387 (2000).
132 15 U.S.C. §§ 2601-2629 (2000).
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Liability Act (CERCLA), 133 the Resource Conservation and Recovery
Act, (RCRA), 134 the Safe Drinking Water Act (SDWA) 135 , and the
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). 136
The environmental statute most likely to first incorporate epi-
genetic assessments is FIFRA, as amended by the 1996 Food Quality
Protection Act (FQPA), which regulates pesticide safety. 13 7 There are
several aspects of FIFRA that would make this statute a particularly
likely candidate for incorporating epigenetic data into risk assessment
and regulatory decisions. First, FIFRA is the only federal environ-
mental statute that requires pre-market safety testing and regulatory
approval of chemical products, in this case pesticides. Before a pesti-
cide can obtain regulatory approval to be commercially distributed, a
prescribed battery of approximately 100 toxicology assays must be
conducted and reported to the EPA in a process called "registra-
tion., 138 Although none of these assays currently directly evaluates
epigenetic effects, it would be relatively straightforward to incor-
porate such an assay into the prescribed battery of tests. Second, the
1996 FQPA amendments require the EPA to develop a testing pro-
gram for endocrine disruptor pesticides, which often involve
epigenetic effects. 139 Finally, FQPA required the EPA to presump-
tively apply an extra ten-fold safety factor to protect children, 40 and
again because epigenetic effects are expected to occur in early devel-
opment, this new provision is also amenable to considering epigenetic
influences.
Notwithstanding these provisions, the EPA has yet to take regula-
tory action or develop a risk assessment method based expressly on
epigenetic risks under FIFRA or any other federal environmental
statute. The potential for a significant epigenetic role in toxicity from
many environmental exposures suggests that new assays may be
needed in safety assessments to evaluate such effects. Direct assess-
ment of epigenetic changes, such as the levels of DNA methylation,
may be warranted in toxicity screening batteries such as those pro-
vided under FIFRA for pesticides. One recent review warned:
' 42 U.S.C. §§ 9601-9675 (2000).
114 2 U.S.C. §§ 6901-6992k (2000).
"' 42 U.S.C. §§ 300f-300j-25 (2000).
136 7 U.S.C. §§ 136(a)-(y) (2000).
137 Food Quality Protection Act of 1996, Pub. L. No. 104-170, 110 Stat. 1489
(codified as amended in scattered sections of 7 U.S.C. and 21 U.S.C.).
138 U.S. ENVTL. PROTECTION AGENCY, PESTICIDES: REGULATING PESTICIDES,
http://www.epa.gov/pesticides/regulating/index.htm (last visited Oct. 28, 2008).
139 21 U.S.C. § 346a(p).
'40 21 U.S.C. § 346a(b)(2)(C)(ii)(II).
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The fact that exposure of a mother to some common environ-
mental agents can result in the persistent chemical modifica-
tion of the genome of the offspring points out to the critical
urgency for screening and identifying environmental epi-
genetic modifiers. Such agents would have escaped detection
using classic assays for genotoxic agents and environmental
hazards.
4 1
Other experts suggest that routine testing for methylation status
may be premature, but that such assessments may be useful to con-
sider on a case-by-case basis. 142 It has also been suggested that DNA
methylation status may be useful as a biomarker of toxicity that could
be used to screen individuals or organisms that have been exposed to
toxic substances. 143 While DNA methylation is being used as a cancer
biomarker, it has not yet been used as a biomarker for evaluating
exposure to and risk from hazardous substances. 144 Given the trans-
generational nature of many epigenetic disruptions, transgenerational
studies will be needed to evaluate some epigenetic-mediated toxicity.
This has significant scientific, economic and legal implications. For
example, insurance policy claims and tort liability may have a "long
tail" if the toxic effects from agents acting via an epigenetic mecha-
nism are not manifested until one or more generations into the future.
Such assays will raise critical issues about the definition of a toxic
or "adverse" effect. Several environmental statutes, including both
FIFRA and TSCA, require manufacturers to report data suggesting
that their products may produce "adverse" effects. Are changes in
DNA methylation alone, which may be or may not be associated with
an increased risk of disease, an "adverse effect" that triggers regula-
tory activity? Some changes in DNA methylation occur naturally,
without any association with toxicity, while others may be caused by
toxic exposures but are transient and reversible.145 Of course, other
DNA methylation changes may indicate a significant toxicological
response. As noted, the issue in trying to distinguish between innocu-
ous and important methylation changes is similar to the issue
involving changes in gene expression following environmental expo-
sures, which sometimes may indicate the early stages of a disease
process, but other times may simply be a reversible, adaptive response
141 Szyf, supra note 14, at 16.
142 Watson & Goodman, supra note 11, at 14.
143 Sutherland & Costa, supra note 10, at 156.
144 Szyf, supra note 14, at 10.
145 Watson & Goodman, supra note 11, at 14.
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to the external stimulus. 46 For example, one recent study found that
exposure to bisphenol-A, which has been found to cause toxic effects
in some animal studies, caused epigenetic changes in the offspring of
exposed mice but no apparent effects on reproductive outcomes, litter
size, or offspring health. 47 Should such epigenetic effects in the ab-
sence of any other detectable toxicity response be considered an
"adverse effect" for regulatory purposes? One policy response that
has been suggested in the literature in the context of other molecular
biomarkers would be only to treat as toxicologically significant those
changes that have been shown to be related to or "anchored" to a
known toxic response. 1
48
The timing of exposure to toxic substances, not just the dose, also
greatly impacts the potential for epigenetic effects. 149 In particular,
exposures to the fetus during the gastrulation stage, or exposures to
newborns, tend to be the most sensitive periods for inducing
epigenetic effects. Traditional toxicology assays generally do not
expose test animals in the fetal or newborn stages, and thus may miss
important toxicity effects mediated through epigenetic mechanisms. 15 °
As the importance of epigenetic influences on toxicity emerges, it
may therefore be necessary to expand the test periods for animal tox-
icity testing to include these sensitive periods.
Studies have also indicated that factors affecting epigenetic pro-
gramming in early development can affect behavior.' 51 It is therefore
possible that early-life exposures to environmental toxins with epige-
netic impacts could manifest in behavioral alterations later in life.
146 See Gary E. Marchant, Genomics and Toxic Substances: Part I - Toxico-
genomics, 33 ENVTL. L. REP. 10071, 10089 (2003).
147 Dolinoy et al., supra note 129, at 13059.
148 Carol J. Henry et al., Use of Genomics in Toxicology and Epidemiology:
Findings and Recommendations of a Workshop, 110 ENVTL. HEALTH .PERSP. 1047,
1049 (2002); COMM. ON APPLICATIONS OF TOxICOGENoMIC TECHNOLOGIES TO
PREDICTIVE TOXICOLOGY, NAT'L RESEARCH COUNCIL, APPLICATIONS OF
TOXICOGENOMIC TECHNOLOGIES TO PREDICTIVE TOXICOLOGY AND RISK ASSESSMENT
187 (2007).149 Dolinoy et al., supra note 85, at 567.
15o See Carl Cranor, The Legal Failure to Prevent Subclinical Developmental
Toxicity, 102 BASIC CLIN. PHARMACOLOGY & TOXICOLOGY 267, 271 (2008) (arguing
for testing of substances for developmental toxicity focusing on the timing of in utero
and postnatal exposures). The National Toxicology Program has recently begun to
include newborn exposure in its chronic carcinogenicity studies, which it had not
routinely done previously, but still does not include prenatal exposures. Kristina A.
Thayer & Paul M. Foster, Workgroup Report: National Toxicology Program Work-
shop on Hormonally Induced Reproductive Tumors - Relevance of Rodent Bioassays,
115 ENVTL. HEALTH PERSP. 1351, 1355 (2007).
151 See supra notes 19, 35-37 and accompanying text.
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Thus, it may be necessary to include behavioral testing in toxi-
cological screening to detect and evaluate such epigenetic toxicity.'
52
Another complication of using epigenetic changes in toxicological
evaluations is that epigenetic changes tend to be highly species-
specific, so that extrapolation from laboratory animals to humans may
be more uncertain than for most other toxicological markers. 53 This
caveat is also shown in the bioinformatics study of the mouse genome,
which predicts 600 imprinted genes, whereas only about 300 are pre-
dicted in humans. For example, the insulin-like growth factor 2 re-
ceptor (IGF2R) gene acts as a tumor suppressor that is imprinted in
mice (i.e., there is only one active copy), whereas both copies of this
gene are expressed in humans (i.e., there is no imprinting). 154 A toxic
agent that causes cancer in mice by knocking out the single active
copy of the IGF2R gene in tha' species may cause cancer much more
infrequently in humans with two active copies of the gene, both of
which must be inactivated to achieve the same cancerous hazard. 55
Another problem is that non-vertebrate species used in some toxicity
testing (including yeast, nematodes, and fruit flies) do not have sig-
nificant DNA methylation, making them even less useful and less
appropriate for evaluating epigenetic changes, even though such mod-
els are widely used for screening for other toxicological endpoints.
56
Toxic environmental agents acting via an epigenetic mechanism
may also be unique in terms of the potential for dietary or other inter-
ventions to mediate their harmful effects. As discussed above,
epigenetic changes differ from traditional genetic changes in that they
are more easily reversed. Studies suggesting that diets rich in methy-
lating agents such as folate or genistein (found in soy) may reverse the
effect of environmental agents that cause DNA hypomethylation
57
For example, maternal dietary supplementation with methyl donors,
such as folic acid, counteracted the epigenetic changes that had been
induced by the chemical bisphenol-A. 58 Such possibilities open the
door to expanding environmental policy approaches from simply pre-
venting toxic exposures to also include interventions designed to miti-
152 Szyf, supra note 14, at 17-18.
153 Jirtle & Skinner, supra note 26, at 253-62. (explaining that
"[u]nderstanding how the environment influences human health and disease will
ultimately require a comprehensive knowledge of the human epigenome, because the
epigenome ... varies markedly between species").
154 Id.
' Id. at 253-62.
156 Szyf, supra note 14, at 10.
57 Jirtle & Skinner, supra note 26, at 255.
158 See Dolinoy et al., supra note 129, at 13059.
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gate the adverse effects of environmental exposures that have already
occurred.
2. Food and Drug Regulation
Epigenetic knowledge has many potential applications in health
care, including both therapeutic and diagnostic uses. The Food and
Drug Administration (FDA) regulates several categories of products
including drugs, medical devices, biologics, foods, and cosmetics, for
the most part under authority provided by the Federal Food, Drug and
Cosmetic Act (FFDCA).15 9 The statute provides different regulatory
criteria for each product category. The product category most likely
to be impacted by epigenetics is prescription pharmaceuticals, which
are required by the FFDCA to be preapproved by the FDA as safe and
effective before they can be marketed. 160 Epigenetic effects can play
both a Dr. Jekyl and Mr. Hyde role in drug development and safety.
On the one hand, a drug that induces unwanted epigenetic effects
might result in unanticipated adverse effects, with both regulatory and
liability repercussions. On the other hand, a drug may be designed to
intentionally induce epigenetic changes to treat diseases with an
epigenetic etiology. And yet other drugs may elicit epigenetic
changes for which no demonstrable outcome can be documented.
Because epigenetic changes tend to be reversible, 161 there is con-
siderable promise and opportunity for the development of epigenetic
drugs to restore a healthy epigenetic status. At least three epigenetic
drugs have already been approved by the FDA, and several more are
now in clinical testing. 162 Given the prevalence within cells of epige-
netic factors in both normal cell development and aberrant conditions,
the use of an epigenetic drug that simply increases or decreases
epigenetic effects such as methylation would be risky because it is
likely to disrupt many other genes in addition to the target gene that is
hypo- or hyper-methylated. 163 Therefore, drugs that more precisely
"9 21 U.S.C. § 301-397 (2000).
160 21 U.S.C. § 355(d) (2000).
161 See supra notes 109, 143 and accompanying text.
162 Gerda Egger et al., Epigenetics in Human Disease and Prospects for Epi-
genetic Therapy, 429 NATURE 457, 460 (2004); Jeneen Interlandi, Chemo Control, :
Drugs Target Epigenetic Changes in Cancer Cells, Sci. AM., April 2007, at 24, 24;
Szyf, supra note 14, at 8. Approved drugs that operate by an epigenetic mechanism
include two that inhibit methylation (Vidaza in 2004 and Dacogen in 2006) that were
approved to treat myelodysplastic syndrome, a blood disorder that can progress to
leukemia, and one drug that enhances acetylation, Zolinza, which was approved in
2006 to treat T cell lymphoma.
163 Andrew P. Feinberg, An Epigenetic Approach to Cancer Etiology, 13
CANCER 1. 70, 73 (2007).
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target the methylation of specific genes, or affect the molecular path-
way leading to the aberrant hypo- or hyper- methylation, are morepromising. 164
The tissue-specific nature of epigenetic effects, in which
epigenetic changes may differ from tissue-to-tissue, may further com-
plicate safety and efficacy testing of drugs. Drugs targeting or af-
fected by epigenetic markers may be more or less effective or toxic in
some tissues than others based on epigenetic status.' 65 New toxico-
logical assays or methods may be needed to address this possibility.' 66
Another potentially important implication of epigenetics in drug
approval is the role of epigenetic factors in drug efficacy and resis-
tance. For example, studies have indicated that hypermethylation of
DNA may be involved in the development of resistance to certain
cancer drugs. 167 This effect may be important both for the regulatory
evaluation of drug efficacy and in developing more effective drugs.
Finally, the observation that early life experiences may alter
epigenetic programming may also have implications for drug safety
and approval. 168 Epigenetic changes to critical genes involved in drug
response as a result of early life experiences could affect subsequent
drug efficacy or toxicity in such individuals. 69 These effects and the
potential impact on variation in drug response within a population
may be another factor to consider in evaluating drug safety.170
Biological response to drug treatment may also be influenced by tran-
sient epigenetic status in ways that can only be documented erratic-
ally, and that may contribute to inter-individual differences in drug
response.
Epigenetic alterations, such as changes in methylation levels at
specific gene locations, can also potentially be used as a diagnostic
indicator for both disease detection and classification. 171 For example,
the tight connection between methylation changes and human cancers
suggests that abnormal methylation patterns could be a useful early
164 Id.
165 Feinberg, supra note 23, at 433-40.
166 Szyf, supra note 14, at 8.
167 Susan H. Wei, Robert Brown & Tim H.M Huang, Aberrant DNA Methyla-
tion in Ovarian Cancer: Is There an Epigenetic Predisposition to Drug Response?,
983 ANN. N.Y. AcAD. Sci. 243, 244 (2003).
168 Szyf, supra note 14, at 8.
169 Id. at 17.
170 Id. at 8, 17.
171 Mukesh Verma & Upender Manne, Genetic and Epigenetic Biomarkers in
Cancer Diagnosis and Identifying High Risk Populations, 60 CRrrICAL REv.
ONCOLOGY/HEMATOLOGY 9, 13 (2006).
[Vol. 19:1
THE GHOST IN OUR GENES
biomarker of cancer before it can be clinically detected.1 72  These
methylation biomarkers can be detected in the blood, as well as other
bodily fluids, including urine, sputum, and breast ductal lavage.
173
Early detection of individuals with epigenetic changes signifying a
cancer risk can be used as a diagnostic measure for prevention:
Hopefully, we will move away from a view of preventive
oncology focusing simply on nonspecific risk factors to iden-
tifying large numbers of patients showing altered epigenetic
risk and targeting them for intervention.... By focusing on
common changes in the population, present in apparently
normal tissue before neoplasms arise, such approaches could
have a substantial impact on cancer morbidity and
mortality.
174
Similarly, detection of methylation changes that occurred in early
development and predispose many individuals to late onset diseases,
such as diabetes, hypertension, and Alzheimer's disease, could be
very useful for diagnosing such diseases early, and even in facilitating
prevention or treatment of such diseases before they are clinically
detected. 175  DNA methylation patterns can also be used to classify
disease, for example to subdivide tumors that were previously indis-
tinguishable into separate subcategories that have different prognoses
and treatment options. 176 Thus, epigenetic markers may be used for
diagnosis, prognosis, and prediction of response to treatment.
177
Already, some companies have begun to offer commercial epigenetic
tests for such purposes, which may require FDA approval. 1
78
172 See Herceg & Hainaut, supra note 28, at 33.
173 Id.
174 Feinberg, supra note 163, at 73.
175 Jirtle & Skinner, supra note 26, at 261.
176 Einav Nili Gal-Yam et al., Cancer Epigenetics: Modifications, Screening
and Therapy, 59 ANN. REV. MED. 267, 274 (2008); Esteller, supra note 47, at 1155.
177 Esteller, supra note 47, at 1155.
178 See Press Release, OncoMethylome Sciences, OncoMethylome Science to
Profile DNA for Abbott Onocology Compounds (Dec. 17, 2007) (stating that its "tests
are designed to help the physician (i) accurately detect cancer in early stages of cancer
development, (ii) predict a patient's response to drug therapy, and (iii) predict the
likelihood of cancer recurrence."), available at http://www.oncomethylome.com/
newsroom/pressrelease2007_detail.php?version=2&id=aHRcDovL2N3cy5od
Wdpbm9ubGluZS5jb20vTy8xMzczMTQvUFIvMjAwNzEyLzExNzYONzUueG is;
see also Epigenomics, Biomarker Services, http://www.epigenomics.com/
en/biomarker-services/ (last visited Oct. 20, 2008). Another company marketing
epigenetic biomarkers is Epigenomics AG (see www.epigenomics.com).
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In addition to the pharmaceutical and diagnostic device applica-
tions of epigenetics, the FDA has recently confronted potential risks
relating to epigenetics in its consideration of whether to approve food
and milk from cloned animals. As stated previously, the FDA found
that if cloned animals presented any food risks, they would probably
be related to aberrant epigenetic programming of embryos created by
somatic cell nuclear transfer cloning methods. 179 Notwithstanding
concerns about potential epigenetic effects in cloned animals, the
FDA concluded that meat and milk from cloned animals are safe. As
the Washington Post summarized the 968 page FDA risk assessment
of cloned animals released in January 2008:
Finally, there was the overarching problem of deciding which
measures would best predict whether the food was safe. Most
puzzling was whether to take into account the subtle altera-
tions in gene activity, called epigenetic changes, that are
common in clones as a result of having just one parent.
In the end, facing the reality that epigenetics have never been
a factor in assessing the wholesomeness of food, agency
scientists decided to use the same simple but effective stan-
dard used by farmers since the dawn of agriculture: If a farm
animal appears in all respects to be healthy, then presume that
food from that animal is safe to eat.'
80
While the FDA did not allow potential epigenetic effects to block
approval of the sale of products from cloned animals, the FDA will no
doubt focus its attention on epigenetic effects in continuing to monitor
this issue.
3. Occupational Safety and Health Regulation
The Occupational Safety and Health Act of 1970 (the Act)' 8' is
the principal federal law regulating workplace safety and health.
82
The Act, applicable to all employers engaged in a business affecting
interstate commerce,1 83 applies to an estimated six million workplaces
179 See supra note 95 and accompanying text.
180 Rick Weiss, FDA Says Clones Are Safe for Food - Report Finds No Evi-
dence of Risks, WASH. POST, Jan. 15, 2008, at Al.
18' 29 U.S.C. §§ 651-78 (2000).
182 The Federal Mine Safety and Health Act, 30 U.S.C. §§ 801-965 (2000),
regulates mines, and several other laws regulate workplace safety and health in spe-
cific industries. See MARK A. ROTHSTEIN, OCCUPATIONAL SAFETY AND HEALTH LAW
§ 2:15 (2008).
"' 29 U.S.C. § 652(5).
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and 90 million employees.' 84 Pursuant to Section 18 of the Act, 85
twenty-three jurisdictions have received federal approval for state
occupational safety and health plans, which operate to divest the fed-
eral government of jurisdiction and replace it with state oversight con-
taining similar requirements of demonstrated effectiveness. 186  The
Act is enforced by the Assistant Secretary of Labor for Occupational
Safety and Health, who serves as administrator of the Occupational
Safety and Health Administration (OSHA).
The Act requires covered employers to provide to each employee
a workplace "free from recognized hazards that are causing or are
likely to cause death or serious physical harm to his employees. 187
This "general duty clause" may be used as the basis of an enforcement
action brought by the Secretary of Labor ("Secretary") only when no
duly promulgated occupational safety and health standard applies to
the alleged violative conditions. 188 The other main statutory duty of
covered employers is to comply with all applicable occupational
safety and health standards promulgated by the Secretary pursuant to
Section 6 of the Act.' 89 The failure to comply with either the general
duty clause or OSHA standards may result in the Secretary issuing a
citation' 90 and assessing a range of civil and criminal penalties' 9' de-
pending on the categorization and gravity of the violation and other
factors. 192
Section 6(b)(5) of the Act prescribes the substantive requirements
for promulgation of standards regulating toxic substances and harmful
physical agents.' 93 This section of the Act is likely to be the focus of
regulators if the issue of epigenetic effects is considered a proper sub-
ject for OSHA rulemaking. The first issue is whether OSHA authority
extends to the regulation of epigenetic effects, especially when these
effects can be preclinical and subclinical as well as clinical. Section
6(b)(5) provides that in promulgating standards for toxic substances or
harmful physical agents:
184 ROTHSTEIN, supra note 182, § 1:4, at 8.
' 29 U.S.C. § 667.
186 ROTHSTEIN, supra note 182, § 3:2, at 52, § 3:10, at 63. The state plans
cover private sector employers as well as state and local government employers, the
latter of which are excluded from coverage under the federal Act. Id. at 22-25, 49-63.
187 29 U.S.C. § 654(a)(1).
188 Safeway, Inc. v. OSHRC, 382 F.3d 1189, 1194 (10th Cir. 2004). See
ROTHSTEIN, supra note 182, §5:35, at 230-31.
189 29 U.S.C. § 654(a)(2).
190 29 U.S.C. § 658.
191 29 U.S.C. § 666.
192 ROTHSTEIN, supra note 182, §§ 14:9-15.
'9' 29 U.S.C. § 655(b)(5).
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The Secretary . . . shall set the standard which most ade-
quately assures, to the extent feasible, on the basis of the best
available evidence, that no employee will suffer material im-
pairment of health or functional capacity even if such em-
ployee has regular exposure to the hazard dealt with by such
standard for the period of his working life.'
94
Do epigenetic effects constitute "material impairment of health or
functional capacity" if the exposure has not yet caused any symptoms
in the exposed employee? This question has not yet been considered
explicitly by the courts. In one case, United Steelworkers of America
v. Marshall,'9 the court analyzed in a different context whether the
Act authorized the Secretary to regulate the subclinical effects of oc-
cupational exposures. In reviewing the lead standard, the D.C. Circuit
held that the Secretary had established that lead exposure causes sub-
clinical hematological, neurological, renal, and reproductive effects,
that these effects are causally related to clinical lead disease, and
therefore that the subclinical effects constitute "material impair-
ment."'196 Applying this precedent, it would appear that some
epigenetic effects could be considered a material impairment and thus
subject to regulation under the Act. Nevertheless, OSHA would have
to demonstrate that the subclinical epigenetic effects are causally
related to clinical effects.
Although the scientific literature on epigenetic effects in humans
is still quite sparse, it is possible that individuals have varied epi-
genetic responses to exposure to occupational toxins. Thus, another
question to address is whether the Act requires protecting the most
sensitive employees. The language of section 6(b)(5), quoted above,
provides that "no employee will suffer material impairment of health."
Despite this seemingly absolute language, the Supreme Court has held
that the Act does not require regulation to the level of zero risk.197 In
Industrial Union Dep 't, AFL-CIO v. American Petrolium Institute,'
98
the plurality opinion stated that "the statute was not designed to
require employers to provide absolutely risk-free workplaces when-
194 Id.
195 United Steelworkers of America, AFL-CIO-CLC v. Marshall, 647 F.2d
1189 (D.C. Cir. 1980).
196 Id. at 1252-59.
'97 See generally Mark A. Rothstein, Occupational Health and Discrimina-
tion Issues Raised by Toxicogenomics in the Workplace, GENOMICS AND
ENVIRONMENTAL REGULATION 183, 186-87(Gary E. Marchant, Richard R. Sharp, &
Jamie Grodsky eds. 2008).
198 Indus. Union Dep't, AFL-CIO v. Am. Petroleum Inst., 448 U.S. 607
(1980).
[Vol. 19:1
THE GHOST IN OUR GENES
ever it is technologically feasible to do so .. .[but] was intended to
require the elimination, as far as feasible, of significant risks of
harm."' 99 Nevertheless, the plurality supported the concept of "action
level" medical surveillance of employees exposed below the permis-
sible exposure level because surveillance "could ensure that workers
who were unusually susceptible ... could be removed from exposure
before they had suffered any permanent damage. 2 °°
Other possible strategies to reduce epigenetic effects include two
types of medical surveillance: pre-exposure testing for individual sus-
ceptibility to epigenetic changes and post-exposure monitoring of
exposed workers to detect epigenetic effects of exposure.201 Epige-
netic testing in the workplace is likely to be as controversial as
202genetic testing. The use of genetic testing in the workplace has the
potential to invade privacy, undermine individual autonomy, create
stigma and psychological harms, and possibly lead to discrimination
against the individual and his or her family members.20 3 The above
discussion is compounded by the fact that diet alone can change the
epigenome. Accordingly, no workplace genetic or epigenetic testing
program should be considered without overwhelming scientific
evidence of its necessity and efficacy as well as the absence of alter-
natives. It would be a mistake, however, to prohibit genetic and
epigenetic testing in all instances and for all purposes. Epigenetic
testing might be appropriate if it were provided on an optional basis to
199 Id. at 641.
200 Id. at 658.
201 The use of post-exposure surveillance probably would require pre-
exposure testing, as well, to establish a baseline for comparison.
202 On the issue of genetic testing and genetic discrimination in employment,
compare Roger Clegg, Bragdon v. Abbott, Asymptomatic Genetic Conditions, and
Antidiscrimination Law: A Conservative Approach, 3 J. HEALTH CARE L. & POL'Y 409
(2000), Mark .S. Dichter & Sarah E. Sutor, The New Genetic Age: Do Our Genes
Make Us Disabled Individuals Under the Americans with Disabilities Act?., 42 VILL.
L. REv. 613 (1997), and Richard A. Epstein, The Legal Regulation of Genetic Dis-
crimination: Old Responses to New Technology, 74 B.U. L. REv. 1 (1994) (supporting
the use of genetic testing), with Henry T. Greely, Genotype Discrimination: The
Complex Case for Some Legislative Protection, 149 U. PA. L. REv. 1483 (2001)
(explaining that "[t]he federal government should prohibit some uses of genetic in-
formation in decisions by employers and health insurers. ), Deborah Gridley,
Note, Genetic Testing under the ADA: A Case for Protection from Employment Dis-
crimination, 89 GEO. L.J. 973 (2001), and Pauline Kim, Genetic Discrimination, Ge-
netic Privacy: Rethinking Employee Protections for a Brave New Workplace, 96 Nw.
U.L. REv. 1497 (2002) (opposing genetic testing).
203 See Paul W. Brandt-Rauf & Sherry I. Brandt-Rauf, Genetic Testing in the
Worplace: Ethical, Legal, and Social Implications, 25 ANN. REv. PUB. HEALTH 139,
141 (2004); Robert J. McCunney, Genetic Testing: Ethical Implications in the Work-
place, 17 OccUP. MED. 665,668-69 (2002).
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applicants and employees and the results were available only to the
individual. 204 Then, the applicant or employee could decide whether
his or her particularized risks from exposure were acceptable.
The Genetic Information Nondiscrmination Act of 2008
(GINA)205 prohibits employers from discriminating against an
employee (including an applicant) on the basis of genetic information,
or requesting, requiring, or purchasing genetic information about an
employee or a family member of the employee. 20 6 Employees are
generally prohibited from acquiring genetic information, but an
exception applies where the information is used for genetic monitor-
ing of the effects of toxic substances if (1) written notice is provided
to the employee; (2) the employee provides voluntary, written
authorization or the monitoring is required by law; (3) the employee is
informed of individual results; (4) the monitoring is in compliance
with applicable regulations; and (5) the employer receives results only
in aggregate form.20 7 The same general approach should be applied to
monitoring for epigenetic effects of toxic exposures.
One last issue to consider is the possible transgenerational effects
of epigenetic changes. Regulation under the Act is not absolute, and it
involves considering various factors, such as the severity of the risk,
the likelihood of the risk, the latency of the risk, the feasibility of con-
trolling the hazards, and the economic consequences of regulation. It
204 The following guidelines, adapted from recommendations regarding ge-
netic testing in the workplace, would appear to have equal force in the context of
epigenetic testing.
1. Employers have a duty to inform applicants and employees of genetic
markers of increased risk based on occupational exposures.
2. Individuals should have the option of undergoing genetic testing for
these markers at the employer's expense.
3. The testing should be performed by a physician of the individual's
choosing.
4. The results should be available only to the individual.
5. The significance of both a positive and a negative test should be ex-
plained to the individual.
6. The choice of whether to accept the job should be left to the individual.
7. Only in the rare situations where employment of the individual would
constitute a direct, immediate, and severe threat to self or others would the
employer be justified in performing its own genetic testing and excluding
the individual.
Mark A. Rothstein, Genetics and the Work Force of the Next Hundred Years, 2000
COLUM. Bus. L. REv. 371, 395 (2000).
205 Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-223,
122 Stat. 881. For a further discussion of GINA, see infra notes 278-280 and accom-
panying text.
206 42 U.S.C.S. §§ 2000ff-l(a)-(b) (LexisNexis 2008).
207 Id. § 2000ff-l(b)(5)(E).
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remains to be seen whether the possibility of transgenerational epige-
netic effects from certain exposures will be a significant factor influ-
encing increased workplace safety and health regulation.
B. Litigation Applications
Epigenetic effects caused by chemicals and other environmental
agents may provide a new source of litigation and liability under the
common law. Such litigation, especially when it involves second and
third generation effects, would raise a number of novel challenges and
issues. For example, how should statute of limitations rules be ap-
plied? Another issue involves obtaining discovery of medical records
of other family members, including the parents or grandparents who
were initially exposed.
The leading precedent for this type of claim is the litigation con-
cerning DES, which was used widely over a twenty-four year period
until it was found in 1971 to cause severe reproductive illnesses in
daughters of pregnant women who took the drug. "DES was manu-
factured by a variety of companies, and many different types of DES
tablets made by different manufacturers were interchanged freely.,
20 8
Product liability actions were brought against the manufacturers of
DES by daughters of women who ingested it. Although the cases
raised numerous legal issues, such as the plaintiffs' ability to recover
despite the inability to identify the manufacturer or manufacturers of
the pills taken by the plaintiffs' mother, the courts and legislatures of
many states showed a great willingness to overcome the structural or
procedural barriers to recovery.209 However, the third-generation
DES claims brought by the granddaughters of the women who took
DES have not been successful due primarily to the courts' unwilling-
ness as a matter of tort theory and public policy to extend liability to
victims who have a relationship too distant or attenuated from the
actual tortious action ("victim attenuation").210
208 Kaimipono David Wenger, Causation and Attenuation in the Slavery
Reparations Debate, 40 U.S.F. L. REv. 279, 314 (2006).
209 Tracey I. Batt, DES Third-Generation Liability: A Proximate Cause, 18
CARDOZO L. REV. 1217, 1223-29 (1996) (the barriers include statutes of limitations,
identification of the particular manufacturer, and jurisdiction over the defendants).
210 Wenger, supra note 208, at 306 -07 (discussing the most commonly con-
tested issues in mass tort litigation that includes the potential but attenuated connec-
tion between the victims, the extent of harm, and the culpability of the alleged wrong-
doers. Further, identifying a responsible manufacturer from among a pool in a large
market creates a problem of wrongdoer attenuation, connecting a harm to later vic-
tims, such as children and grandchildren, of the original product consumer creates a
problem of victim attenuation and establishing the causal connection between the
wrongdoer's product and the later victim's harm faces a problem of act attenuation).
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McMahon v. Eli Lilly & Co. 211 is the first reported appellate deci-
sion involving a third-generation DES claim. The plaintiff mother
had several children born prematurely and one premature infant
died.212 The parents ("plaintiffs") sued the defendant-drug company
claiming that the mother's in utero exposure to DES when her mother
(the maternal grandmother) ingested the drug produced by the defen-
dant was the cause of the death of their infant son.2 13 The court re-
versed the lower court's grant of defendant's directed verdict, based in
part on the plaintiffs' failure to make a prima facie showing that the
defendant manufactured the drug to which the mother was exposed.214
The court held that the evidence showing that the defendant was the
wholesale supplier of DES to the drug store where the drug was ob-
tained by the maternal grandmother of the deceased infant was suffi-
cient to establish culpability.215 The court also stated that the lower
court's requirement of the foreseeability by the defendant of the
specific risk to the third generation was far too narrow.2 16 The court
found that medical research was then published and reported experi-
ments showing that DES could cause physical abnormalities in the
reproductive tracts of animals exposed to the drug in utero.2 17 The
court reasoned that these reports explicitly suggested the drug's poten-
tial dangers to humans as well as animals.21 8 The court thus con-
cluded that this evidence was more than sufficient to support a jury
verdict for the plaintiffs.219 Therefore, the court reversed the directed
verdict for the defendant and remanded the case for a new trial.220
211 774 F.2d 830 (7th Cir. 1985).
212 Id. at 832.
213 Id. at 831-32.
214 Id. at 832, 834.
215 Id. at 832-34.
216 Id. at 835. ("This ruling frames the question of foreseeability far too nar-
rowly. Under Illinois precedent, to prevail on a failure to warn claim, a plaintiff must
show 'that the manufacturer knew or should have known of the danger presented by
the use or consumption of the product' and that the manufacturer did not warn of the
product's 'dangerous propensities.' Plaintiffs need not prove that Lilly should have
anticipated the precise injuries allegedly suffered, so long as the injuries lay within
the scope of the known dangerous propensities of DES." (quoting Woodill v. Parke
Davis & Co., 402 N.E.2d 194, 198 (Ill. 1980))); Id at 835 n.7 ("[The plaintiff]'s
treating physician, an expert witness, testified that it was 'more likely than not' that
[her] injuries were caused by prenatal exposure to DES. This testimony was suffi-
cient to allow the jury to consider the question.").
217 Id. at 834.
218 Id.
219 Id. at 835-36.
220 Id. at 838.
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This ruling was much more favorable to the third-generation DES
claimant than subsequent decisions from other courts.
To avoid ipjustice in DES litigation, the New York legislature and
the New York Court of Appeals removed legal barriers to tort re-
covery in DES-daughter cases for the special circumstances in the
DES context.221 In 1986, the legislature amended the law to provide
that the limitations period in exposure cases begins upon discovery of
the injury instead of upon the exposure.22 In 1989, the New York
Court of Appeals held, in Hymowitz v. Eli Lilly & Co., that liability
could be imposed upon DES manufacturers based on their share of the
national DES market, notwithstanding the plaintiff's inability to iden-
tify the particular manufacturer at fault for her injuries.223
In Enright v. Eli Lilly & Co., the same court stated that:
[The] recent developments demonstrate legislative and judi-
cial solicitude for the victims of DES, but they do not estab-
lish DES plaintiffs as a favored class for whose benefit all
traditional limitations on tort liability must give way. To the
extent that special rules have been fashioned, they are a re-
sponse to unique procedural barriers and problems of proof
peculiar to DES litigation. 24
The court suggested that removing such a legal barrier in the con-
text of third-generation DES cases would affect the substantive law of
tort; therefore, the court refused, largely based on policy considera-
tions, to extend the strict products liability recovery to third genera-
tion plaintiffs.225
In Enright, the court treated the DES-granddaughter injury as a
"preconception tort" committed against the mother, and thus pre-
cluded the tort claim based on the bright-line "no duty rule"
226
developed in Albala v. City of New York.227 However, as in Albala,
the Enright court stated that to recognize a cause of action on behalf
221 Hymowitz v. Eli Lilly & Co., 539 N.E.2d 1069, 1080 (N.Y. 1989) (ex-
plaining that "DES victims were prejudiced under current law" and that "[t]he Legis-
lature does not violate equal protection by providing a rational piecemeal remedy for
what may be a larger problem").
222 Id. at 1079.
223 Id. at 1075.
224 570 N.E.2d 198, 201-02 (N.Y. 1991).
225 Id. at 204.
226 Id. at 201.
227 Albala v. City of N.Y., 429 N.E.2d 786, 787 (N.Y. 1981). InAlbala, the
child was born with brain damage allegedly attributable to the defendants' negligence
in perforating the mother's uterus in the course of an abortion four years earlier.
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of the DES-granddaughter "would require the extension of traditional
tort concepts beyond manageable bounds. '2 8  Further, the court in
Enright stated that "[l]imiting liability to those who ingested the drug
or were exposed to it in utero serves this purpose. ' 229 Implicitly, these
holdings suggest that the court considered that the relevant injury was
to the mother and the DES-daughter, but not to the later-conceived
grandchild, thus undercutting the duty of care to the DES-
granddaughter altogether.
Among a score of unsuccessful third-generation DES cases in
different jurisdictions,23 ° the Enright case is the most controversial in
that it is the least consistent with its jurisdiction's DES and proximate
cause precedents, where the court had allowed for recovery of proxi-
mate injuries, but not remote ones.231  The court used the policy
argument of needing to put some limits on liability to draw the line
between the second and third generations, without explaining why it
did not draw the line between the third and fourth generations.232 In
Enright, the court "seemed to have difficulty deciding where to draw
the line between proximate and remote consequences, between prop-
erly compensating victims and not holding drug manufacturers liable
in perpetuity. '233 "The types of injuries at issue here are not ones that
involve multigenerational genetic damages. Instead, they are a direct
result of the compensable injuries to the DES-daughters. In denying
[their] recovery. . . ,the New York Court of Appeals ignored tradi-
tional doctrines that impose reasonable limitations on tort liability
while compensating plaintiffs directly injured by defendants.' 234
Further, Judge Hancock stated that if it was foreseeable that the DES-
daughter's in utero exposure might cause defects in her reproductive
system, "[c]learly it cannot be said as a matter of law" that it was not
foreseeable that the DES-granddaughter would be born with
injuries.235
228 id.
229 Enright, 570 N.E.2d at 203.
230 In addition to New York, several other jurisdictions have rejected third-
generation DES injury cases using various and divergent theories. See Sorrells v. Eli
Lilly & Co., 737 F. Supp. 678 (D.D.C. 1990) (holding that manufacturer owed no
duty under Maryland law, which at this time does not extend to unborn granddaughter
of person who had ingested DES); DeMayo v. Schmitt, 5 Pa. D. & C. 4th 197, 200
(Pa. Com. Pl. 1989) (rejecting strict liability claims, but suggesting negligence claims
may be viable in appropriate circumstances).
231 Enright, 570 N.E.2d at 206 (Hancock, Jr., J., dissenting).
232 Id. at 203.
233 Batt, supra note 209, at 1242.
234 id.
235 id.
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In Grover v. Eli Lilly & Co., an Ohio Supreme Court third-
generation-DES case, the court decided that "[a] pharmaceutical com-
pany's liability for the distribution or manufacture of a defective
prescription drug does not extend to persons who were never exposed
to the drug, either directly or in utero."236 This decision also has been
criticized. Justice Resnick stated in his dissenting opinion:
What could have a more direct causal connection than a pre-
mature birth by a woman who was known to have an incom-
petent cervix? From this it becomes readily apparent that
DES grandchildren were a foreseeable group of plaintiffs. It
can hardly be argued that there is no duty owed to a
foreseeable plaintiff.237
Finally, as John B. Maynard succinctly summarized:
Once the tired old arguments about the opening of the flood-
gates of litigation are stripped away; once the sound justifica-
tion for imposing a reasonable duty of care on drug manufac-
turers is recognized; and once the exaggerations about the
inhibitions of medical researchers are put in perspective, it
should be the law that the third-generation-DES claim
presents a valid cause of action deserving of a remedy.238
Third-generation DES claims have not been successful due to the
courts' interpretation of a victim attenuation problem in the 1980s.
However, with the emergence of epigenetics; the acceptance of epige-
netics' hypothetical role as an added layer of regulation in genetic
common diseases (CDGE, Common Disease Genetic and Epigenetic
hypothesis),239 or more broadly, the recognition that P (phenotype) =
G (Genes) + E (Environment) + EpiG (Epigenetics)), 240 the
"attenuation problem" in the DES-granddaughter tort claims may
deserve a reevaluation based on the gradual discovery of underlying
mechanisms of transgenerational epigenetic diseases.
236 Grover v. Eli Lilly & Co., 591 N.E.2d 696, 700-01 (Ohio 1992).
237 Id. at 703 (Resnick, J. dissenting).
238 John B. Maynard, Third-Generation-DES Claims, 27 NEW ENG. L. REv.
241, 285 (1992).
239 Feinberg, supra note 23, 438.
240 Arturas Petronis, Epigenetics and Twins: Three Variations on the Theme,
22 TRENDS GENETIcs 347, 348 (2006).
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C. Discrimination in Employment Against Fertile Women
Human susceptibility to epigenetic insults varies over the course
of a lifetime, with increased vulnerability occurring, among other
times, in utero.241 Thus, the issue is raised whether some employers
could prohibit fertile women from working where there is exposure to
substances suspected of causing epigenetic harms. The purpose of
such exclusion would be to prevent harms to the later-born children of
female employees and to reduce the likelihood of personal injury
claims brought by those children based on their in utero exposure.
Adverse health effects also might extend to the offspring of the pre-
natally exposed children and, conceivably, even to future generations.
Similar employment discrimination concerns already have been
addressed in the context of maternal exposure to teratogenic sub-
stances in the workplace.243 In UAW v. Johnson Controls, Inc., the
employer was concerned about its possible liability if a pregnant em-
ployee was occupationally exposed to inorganic lead and later gave
birth to a child with congenital defects caused by the mother's work-
place exposure. 2" Under the metabolic stress of pregnancy, lead
stored in the mother's bones may be released into her bloodstream and
then into the fetus.245 Thus, female employees could transmit lead to
a developing fetus from preconception exposures. 246 Furthermore, the
241 Jirtle & Skinner, supra note 26, at 253-62 (discussing study results that
support the hypothesis of "fetal basis" or "developmental origins of adult-onset dis-
ease," a theory supported by increasing evidence that "environmental influences early
in development are linked to disease phenotypes through modifications of the epige-
nome").
242 Although the employee-mother would be barred by workers' compensa-
tion from bringing a personal injury action for the injuries caused by her own expo-
sure, the child of an employee may not be prohibited from bringing an action based
on in utero exposure. Compare Snyder v. Michael's Stores, Inc., 945 P.2d 781 (Cal.
1997); Omori v. Jowa Hawaii Co., Ltd., 981 P.2d 714 (Haw. Ct. App.), aff'd as
mod'd, 981 P.2d 703 (Haw. 1999); and Cushing v. Time Saver Stores, Inc., 552 So.
2d 730 (La. Ct. App. 1989) (action not barred by workers' compensation) with
Widera v. Ettco Wire & Cable, 611 N.Y.S.2d 569 (App. Div. 1994), appeal denied,
626 N.Y.S.2d 755 (1995) (employer owed no duty to child in utero).
243 In humans, the most sensitive period for birth defects caused by in utero
exposure to teratogens is generally considered between weeks two and 12 of gesta-
tion. David Eaton, Toxicology, in TEXTBOOK OF CLINICAL OCCUPATIONAL AND
ENviRONMENTAL MEDICINE 83, 89 (Linda Rosenstock et al. eds., 2005).
244 499 U.S. 187, 190-92 (1991).
245 Jacqueline M. Moline & Philip J. Landrigan, Lead, in TEXTBOOK OF
CLINICAL OCCUPATIONAL AND ENVIRONMENTAL MEDICINE 967, 971 (Linda Rosen-
stock et al. eds. 2005).
246 Id.
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fetus is most sensitive to lead exposure in the early stages of preg-
nancy, when many women do not even know they are pregnant.247
Because of the possible health risks to the fetus and financial risks
to the company, Johnson Controls adopted a "fetal protection policy"
that barred all fertile women - regardless of their marital status,
reproductive plans, or other considerations - from any job likely to
elevate their blood lead above a certain level.248 The Supreme Court
held that that the employer's policy constituted sex discrimination in
violation of Title VII of the Civil Rights Act of 1964.249 The Court
held that by excluding only women with childbearing capacity from
jobs with lead exposure, the employer's policy was explicit, disparate
treatment discrimination, which could only be upheld by applying a
bona fide occupational qualification (BFOQ) defense.25 °
The Court interpreted the statutory defense of BFOQ under Title
251VII as narrow. It permits discrimination based on gender only in
limited circumstances where discrimination is "'reasonably necessary'
to the 'normal operation' of the 'particular' business. 252 Although
safety concerns may establish a BFOQ, "the safety exception is lim-
ited to instances in which sex or pregnancy actually interferes with the
employee's ability to perform the job. 253  Because fertile women
were capable of performing the job, the Court concluded that the
employer failed to establish the BFOQ defense.5 Of particular rele-
vance to transgenerational epigenetics, the Court said that concerns
about the welfare of the next generation did not establish a BFOQ of
female sterility. "Decisions about the welfare of future children must
be left to the parents who conceive, bear, support, and raise them ra-
ther than to the employers who hire those parents. 255
In the years since the Court's decision in Johnson Controls, new
scientific discoveries have documented the significant risks from early
247 See Laura S. Welch, Decisionmaking About Reproductive Hazards, 1 SEM.
OCCup. MED. 97, 105 (1986).
248 UAW, 499 U.S. at 191-92.
249 See UAW, 499 U.S. at 211.
250 UAW, 499 U.S. at 200.
251 Id. at 201. Section 703(e) of Title VII provides, in pertinent part, that "it
shall not be an unlawful employment practice for an employer to hire and employ
employees . . . on the basis of his religion, sex, or national origin in those certain
instances where religion, sex, or national origin is a bona fide occupational qualifica-
tion reasonably necessary to the normal operation of that particular business or enter-
prise... " 42 U.S.C. § 2000e-2(e) (2000).
252 Int'l Union, 499 U.S. at 201.
253 Id. at 204.
254 Id. at 206.
255 Id.
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life exposures, including prenatal exposures, to various toxic sub-
stances. Among the risks associated with certain early exposures are
neurological harms,256 cardiovascular harms,2 7 and increased risk of
cancer. 58 Will the multigenerational harms implicated by epigenetics
lead to a reconsideration of the Johnson Controls preference for
worker autonomy over employer paternalism and the desire to protect
future generations? Although the health of future generations - both
proximate and remote - is a vital consideration, increased trans-
parency and vigilance with regard to occupational health hazards is
preferable to authorizing vast exclusionary practices affecting female
applicants and employees. Some of the methods of protecting against
transgenerational harms of any etiology or manifestation are substitu-
tion of substances, improved environmental controls, personal pro-
tective equipment, medical surveillance, optional and confidential
fertility and pregnancy testing, and optional medical removal with
maintenance of pay and benefits for workers who are or are attempt-
ing to become pregnant.259
D. Other Forms of Discrimination
Many other claims for alleged epigenetics-based discrimination
are possible. In the employment setting, the first issue is whether an
epigenetic mark or the predisposition to epigenetic changes constitutes
a disability under the Americans with Disabilities Act (ADA)260 or its
state analogs. 261 Applying current case law, it is unlikely that a court
would hold that an epigenetic change or predisposition to an epige-
netic change is an impairment that constitutes a "substantial limitation
256 Deborah Rice & Stan Barone, Jr., Critical Periods of Vulnerability for the
Developing Nervous System: Evidence from Humans and Animal Models, 108 ENVTL.
HEALTH PERSP. (SuPP. 3) 511 passim (2000).
257 See David J.P. Barker, Fetal Programming of Coronary Heart Disease 13
TRENDS iN ENDOCRINOLOGY & METABOLISM 364,364 (2002).
258 See Hugh A. Barton et al., Assessing Susceptibility from Early-Life Expo-
sure to Carcinogens, 113 ENVTL. HEALTH PERSP. 1125, 1125 (2005); see also Jennifer
D. Cook et al., Interaction Between Genetic Susceptibility and Early-Life Environ-
mental Exposure Determines Tumor-Suppressor-Gene Penetrance, 102 PROC. NAT'L.
ACAD. Sci. 8644 (2005).
259 See generally Elaine Draper, Reproductive Hazards and Fetal Exclusion
Policies After Johnson Controls, 12 STAN. L. & POL'Y REv. 117 (2001) ("Greater
awareness of reproductive hazards, along with new technologies for detecting them,
can indeed serve useful ends in improving public health.").
260 42 U.S.C. §§ 12101-12213 (2000).
261 Virtually every state has enacted a law prohibiting discrimination in em-
ployment on the basis of disability. MARK A. RoTHsTEiN ET AL., EMPLOYMENT LAW §
3.15 (3d ed. 2004).
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of a major life activity. '262 In Sutton v. United Air Lines, Inc.,263 the
Supreme Court adopted a narrow view of the coverage of the ADA.
The Court observed that the ADA's findings section264 specifically
states that "some 43,000,000 Americans have one or more physical or
mental disabilities, and this number is increasing as the population as
a whole is growing older., 265 Thus, the Court reasoned that the ADA
was not intended to cover individuals whose impairments may be
mitigated through the use of eyeglasses and other corrective measures.
Similar reasoning would undermine the claim that an asymptomatic
individual with an epigenetic change is an individual with a disability
under the ADA.266
Two-thirds of the states have enacted laws prohibiting genetic
267discrimination in employment. At the federal level, the recently
enacted Genetic Information Nondiscrimination Act (GINA) 268 pro-
hibits discrimination in employment on the basis of genetic informa-
tion. Although state laws differ in their definition of genetic informa-
tion, many state enactments are similar to GINA, which defines
genetic information as "information about [an] individual's genetic
tests, the genetic tests of family members of such individual, and the
manifestation of a disease or disorder in family members of such indi-
vidual., 269 Scientifically, epigenetic information is not genetic infor-
mation, and therefore it probably would be necessary to amend state
262 42 U.S.C. §12102(2) defines "disability" as: "(A) a physical or mental
impairment that substantially limits one or more of the major life activities of such
individual; (B) a record of such an impairment; or (C) being regarded as having such
an impairment." 42 U.S.C. § 12102(2) (2000).
263 Sutton v. United Airlines, Inc., 527 U.S. 471 (1999).
264 42 U.S.C. § 12101(a)(1).
265 Sutton, 527 U.S. at 484 (quoting 42 U.S.C. § 12101(a)(l)). See generally
Ruth Colker, The Mythic 43 Million Americans with Disabilities, 49 WM. & MARY L.
REv. 1 (2007) (discussing the Court's interaction with Congress and the limits of the
ADA's disability discrimination protections).
266 Another line of ADA cases makes it clear that minor or temporary im-
pairments are not covered under the statute. See, e.g., Chanda v. Engelhard/ICC, 234
F.3d 1219 (1 1th Cir. 2000) (holding employee's tendonitis did not substantially limit
his performance of manual tasks); Leisen v. City of Shelbyville, 153 F.3d 805 (7th
Cir. 1998) (depression); Kelly v. Drexel Univ., 94 F.3d 102 (3d Cir. 1996) (post-
traumatic degenerative joint disease, which caused moderate difficulty walking or
climbing stairs).
267 For an updated list of all state laws, see NAT'L CONFERENCE OF STATE
LEGISLATURES, STATE GENETICS EMPLOYMENT LAWS, http://www.ncsl.org/programs/
health/genetics/ndiscrim.htm (last visited Oct. 21, 2008).
268 Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-223,
122 Stat. 881. See Mark A. Rothstein, Putting the Genetic Information Nondiscrimi-
nation Act in Context, 10 GENETICS IN MED. 655 (2008).
269 42 U.S.C.S. §2000ff(4)(A) (LexisNexis 2008).
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and federal nondiscrimination laws to prohibit discrimination based
on epigenetic factors.27° Consequently, an employer concerned about
possible epigenetic effects on employees perceived to be susceptible
to occupational exposures could simply refuse to employ the indivi-
dual or assign the individual to other tasks. Clearly, genetic non-
discrimination laws should be amended or new legislation should be
enacted to prohibit such practices.
There are also many possible uses of epigenetic information in in-
surance underwriting. The vast majority of states have enacted laws
prohibiting genetic discrimination in health insurance. 27' At the fed-
eral level, GINA prohibits discrimination in health insurance on the
basis of genetic information. The state and federal approaches vary in
their coverage and definitions, but, as with the employment discrimi-
nation laws discussed above, none of the laws are likely to cover epi-
genetic conditions.272 Epigenetic information might be used to predict
future health in any of the myriad situations where genetic informa-
tion is now used or where there is concern about possible use, such as
life insurance, 273  disability insurance,2 74  and long-term care
insurance.275
270 Even if such legislation were seriously considered, it may not be effective
if it uses the same approach as GINA, because current laws do not prohibit the disclo-
sure of detailed clinical records (which might contain genetic or epigenetic informa-
tion) pursuant to a compelled authorization after a conditional offer of employment.
See Mark A. Rothstein & Meghan K. Talbott, Compelled Disclosure of Health Infor-
mation: Protecting Against the Greatest Potential Threat to Privacy, 295 JAMA
2882, 2882 (2006). Furthermore, it is difficult to justify affording special treatment to
genetic or epigenetic information than other predictive health information. See Mark
A. Rothstein, Genetic Exceptionalism and Legislative Pragmatism, HASTINGS CENTER
REP., Julr-Aug. 2005, at 27, 31-32.
1 For an updated list of all state laws, see NAT'L CONFERENCE OF STATE
LEGISLATURES, GENETICS AND HEALTH INSURANCE STATE ANTI-DSCRIMNATION
LAWS, http://www.ncsl.org/programs/health/genetics/ndishlth.htm (last visited Oct.
25, 2008) A significant limitation on the effectiveness of these laws is that they only
prohibit discrimination against individuals who are asymptomatic. If an individual
becomes affected, then the health insurance company may decline to renew or may
increase the cost of the policy to the degree permitted by state insurance laws. For
employment-based group health plans, the Health Insurance Portability and Account-
ability Act (HIPAA), prohibits any discrepancy in pricing or coverage based on health
condition. 42 U.S.C. § 300gg-l(a)(l) (2000). This significant shortcoming under-
scores the need for more comprehensive approaches. See Rothstein, supra note 268,
at 655-56.
273 See generally GENETICS AND LIFE INSURANCE: MEDICAL UNDERWRITING
AND SOCIAL POLICY (Mark A. Rothstein ed., 2004) (exploring the proper policies for
using genetic information in life insurance coverage determinations).
274 See generally Symposium, Genetic Testing and Disability Insurance, 35
J.L. MED. & ETHICS (SPECIAL SuPP.) 5 (2007) (providing the first ever in-depth study
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The discovery of epigenetic effects in humans further undermines
the viability of genetic-specific nondiscrimination legislation. Legis-
lation prohibiting the inappropriate use of predictive health informa-
tion is more logical from a scientific and policy standpoint because it
focuses on the effect of future health risks on current opportunities
rather than on the biological mechanism by which the harm may be
manifested.
IV. ETHICAL IMPLICATIONS
As a relatively new field of research, epigenetics has the potential
to raise a variety of issues related to research ethics, such as conflicts
of interest, research integrity, informed consent, and privacy. As sci-
entists apply epigenetics to human health, concerns about clinical
ethics and public health ethics are likely to arise. It is not clear if or
how the epigenetic applications of these issues will differ from the
well-considered context of clinical genetics or public health genetics.
Therefore, in this section we have chosen to focus on the unique
ethical implications of epigenetics in the following broad areas: envi-
ronmental justice, privacy and confidentiality, access to health care,
intergenerational equity, and eugenics.
A. Environmental Justice
Toxic chemicals, airborne pollutants, pesticides, diesel exhaust,
tobacco smoke, and other harmful exposures are not distributed ran-
domly throughout society.276  The exposures are frequently linked
with poverty, discriminatory land use, and substandard living and
working conditions.277 Populations exposed to environmental insults
also are more likely to have pre-existing health conditions, often with278
poor clinical management. As discussed previously, some common
of genetic testing and disability insurance, through various essays written by a diverse
group of experts, including scholars in law, health care, ethics, public policy, public
health, and professionals from the insurance industry).
275 See Cathleen D. Zick et al., Genetic Testing for Alzheimer's Disease and
its Impact on Insurance Purchasing Behavior, 24 HEALTH AFFAIRS 483, 483 (2005)
(stating that "[i]f genetic testing for Alzheimer's risk assessment becomes common, it
could trigger adverse selection in long-term care insurance").
2 See generally THE QUEST FOR ENViRONMENTAL JUSTICE: HUMAN RIGHTS
AND THE POLITICS OF POLLUTION (Robert D. Bullard ed., Sierra Club Books 2005)
(discussing the disparate impact of environmental pollution on minorities and the
poor).
277 Id.
278 See generally RICHARD G. WILKINSON, UNHEALTHY SOCIETIES: THE
AFFLICTIONS OF INEQUALITY (1996) (discussing pathways through which inequality
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environmental exposures may have epigenetic effects. 279 Assuming
that epigenetic changes adversely affect the most vulnerable segments
of society, it could be argued that there is a heightened moral obliga-
tion to remediate the environmental sources of risk and prevent future
harmful exposures. On the other hand, if the most vulnerable people
are considered at greatest risk, as a practical matter, the political
resolve of policy makers might be lessened.280
"Environmental justice refers to a political and social movement
to address the disparate distribution of environmental harms and bene-
fits in our society, and to reform the processes of environmental deci-
sion making so that all affected communities have a right to meaning-
ful participation., 28 1  The debate over environmental justice raises
important distributive issues for environmental law,282 and it has led to
great controversy. Claims about environmental justice have been
termed "unsettling" to supporters of strong environmental protection
because they "sound disturbingly reminiscent of accusations of elitism
that environmental activists have long heard and long discounted.,
283
Thus, there may be a tension between some traditional environmental-
ists and advocates of environmental justice.284 More overt critics of
environmental justice have asserted that claims for environmental
and loss of social cohesion are likely to affect health).
279 See supra notes 66-84, 101-05 and accompanying text.
280 See Robert W. Williams, Environmental Injustice in America and Its Poli-
tics of Scale, 18 POL. GEOG. 49-73 (1999) (discussing politics of environmental jus-
tice).
281 Clifford Rechtschaffen, Advancing Environmental Justice Norms, 37 U.C.
DAVIS L. REV. 95, 96 (2003). The EPA uses the following definition: "Environmental
Justice is the fair treatment and meaningful involvement of all people regardless of
race, color, national origin, or income with respect to the development, implementa-
tion, and enforcement of environmental laws, regulations, and policies." U.S. Envi-
ronmental Protection Agency, Environmental Justice, http://www.epa.gov/compliance
/environmentaljustice (last visited Oct. 24, 2008). See generally DAVID
SCHLOSSBERG, DEFINING ENVIRONMENTAL JUSTICE: THEORIES, MOVEMENTS, AND
NATURE (Oxford Univ. Press 2007) (arguing that any definition of environmental
justice needs "a broadly accessible, plural, and workable frame."). Environmental
justice also has been referred to as environmental racism and environmental equity.
Gerald Torres, Environmental Justice: The Legal Meaning of a Social Movement, 15
J.L. & COM. 597, 603 (1996).
282 Richard J. Lazarus, Essay, Fairness in Environmental Law, 27 ENVTL. L.
705,715 (1997).
283 Id. at 714.
284 But see Peter Wenz, Does Environmentalism Promote Injustice for the
Poor? In ENVIRONMENTAL JUSTICE AND ENVIRONMENTALISM: THE SOCIAL JUSTICE
CHALLENGE TO THE ENVIRONMENTAL MOVEMENT 57-83 (Ronald Sandler & Phaedra
C. Pezzullo eds., 2007).
[Vol. 19:1
THE GHOST IN OUR GENES
justice lack empirical foundations 285 and that there is little evidence to
support the claim of disproportionate burdens on minorities because
"locally undesirable land uses are attributable largely to the workings
of the market.,
286
The environmental justice movement began in the 1970s and
1980s with civic activism, protests, and litigation.287 In the 1990s,
two events gave it major impetus. First, in 1992, the EPA published
the report of a workshop on environmental equity that concluded that
minorities experienced disproportionately greater exposure to envi-
ronmental pollutants.288 Later that year, the EPA created the Office of
Environmental Equity (the name was later changed to the Office of
Environmental Justice) to oversee environmental justice at the agen-
cy.289 Second, in 1994, President Clinton issued an executive order
requiring all federal agencies to make environmental justice part of
their mission by identifying and addressing, as appropriate, "dispro-
portionately high and adverse human health or environmental effects"
of its programs, policies, and activities "on minority populations and
low-income populations.
'
,
290
Epigenetics could change the traditional environmental justice
analysis in three important ways. First, in some cases it could shift
the focus from populations receiving disproportionate exposure to
those with greater susceptibility. Second, rather than focusing on
geographically defined communities, it concentrates on the individual
biological factors that establish increased risk. Third, it does not
directly address the differential exposures caused by race and ethnic-
285 William Bowen, An Analytical Review of Environmental Justice Research:
What Do We Really Know?, 29 ENvTL. MGMT. 3 (2002).286 Torres, supra note 281, at 607. Vicki Been, Locally Undesirable Land
Uses in Minority Neighborhoods: Disproportionate Siting or Market Dynamics?, 103
YALE L.J. 1383 (1994), quoted in Torres, supra note 281. Contra Manuel Pastor, Jr.,
Jim Sadd & John Hipp, Which Came First? Toxic Facilities, Minority Move-in, and
Environmental Justice, 23 J. URB. AFF. 1, 1-21 (2001) (finding that minorities attract
toxic storage and disposal facilities).
287 Tseming Yang, Melding Civil Rights and Environmentalism: Finding
Environmental Justice's Place in Environmental Regulation, 26 HARv. ENvTL. L.
REv. 1,4-8 (2002).
288 ENvT. PROTECTION AGENCY, OFFICE OF POLICY PLANNING AND
EVALUATION, ENVIRONMENTAL EQUITY: REDUCING RISK FOR ALL COMMUNITIES, 12
(1992). See Eric K. Yamamoto & Jen-L W. Lyman, Racializing Environmental Jus-
tice, 72 U. COLO. L. REv. 311,318 (2001).
289 See Office of Environmental Justice, http://www.epa.gov/compliance
/environmentaljustice (last visited Aug, 15, 2008).
290 Federal Actions to Address Environmental Justice in Minority Populations
and Low-Income Populations, Exec. Order No. 12,898, 59 Fed. Reg. 7,629 (Feb. 16,
1994).
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ity, although some epigenetic marks have different frequencies in
certain subpopulations.291
In addition, viewing environmental epigenetics in light of envi-
ronmental justice raises the issue of whether it is prudent to concen-
trate on the problems of vulnerable populations when there are global
concerns. According to one line of reasoning:
If we are unable to solve globally pressing problems such as
ozone depletion, climate change, or the loss of biodiversity,
we might not have an environment, or a planet, left that is
hospitable to human society. Without an effective and expe-
ditious solution to such larger problems, there will be nothing
left for racial minorities or the poor to live in, or for that mat-
ter anyone else.292
Nevertheless, the global scale of overall environmental challenges
should not divert attention from addressing environmental in-
justices, 293 especially when the harms associated with exposures
threaten the health of future generations in a self-perpetuating cycle of
poor health and reduced quality of life.
There are no easy solutions to the problems of environmental
justice, which must be considered along with the other "emerging
ideals" of environmental policy-sustainable development, ecosystem
management, and pollution prevention.294 Environmental justice also
is related to economic justice, human rights, social equality, and
public health.295 It remains to be seen whether emerging scientific
evidence of epigenetic effects, including transgenerational effects,
will be a catalyst for environmental justice.
B. Privacy and Confidentiality
Epigenetics could create a wealth of sensitive information about
an individual's likelihood of developing health problems in the future
291 See Gary E. Marchant & Jamie A. Grodsky, Genomics and Environmental
Justice: Some Preliminary Thoughts, GENOMICS AND ENvIRONMENTAL REGULATION
(Richard R. Sharp, Gary E. Marchant & Jamie A. Grodsky eds. 2008) (recognizing
these distinctions between traditional environmental justice analysis and environ-
mental justice influenced by genetic susceptibility).
292 Yang, supra note 287, at 30.
293 Environmental justice is a global concern. See Luz Claudio, Standing on
Principle: The Global Push for Environmental Justice, 115 ENVTL. HEALTH PERsP. A
501 (2007) (summarizing the environmental justice movement).
294 Torres, supra note 281, at 617.
295 See, e.g., Charles Lee, Environmental Justice: Building a Unified Vision of
Health and the Environment, 110 ENvTL. HEALTH PERSp. (Sutp. 2) 141 (2002).
[Vol. 19:1
THE GHOST IN OUR GENES
and possibly transmitting the risk to his or her offspring. More sensi-
tive health information is likely to lead to greater concerns about
privacy and confidentiality protections at a time when interoperable
networks of health information exchange will make widespread
disclosure of health information increasingly easy.296
"Health information privacy refers to an individual's right to
control the acquisition, uses, or disclosures of his or her identifiable
health data. ' 297 Individuals have various privacy interests with regard
to epigenetic information. If they undergo testing to determine
whether they have developed epigenetic changes based on environ-
mental exposures, they may want to prevent disclosure of the informa-
tion to third parties, such as employers and insurers, as well as to
friends, relatives, and even some health care providers. Among the
issues raised are whether any restrictions may be placed on an indi-
vidual's desire for privacy; whether individuals have a moral or legal
duty to warn other at-risk individuals, including family members; and
if some exposed individuals prefer not to undergo testing, especially
when there is no medical intervention, whether they should have a
right not to know.298
"Confidentiality, which is closely related [to privacy], refers to the
obligations of those who receive information to respect the privacy
interests of those to which the data relate. 299 It is the basis of profes-
sional standards of conduct and legal obligations.300 Issues surround-
ing confidentiality include determining what standard should be used
in assessing an individual's consent or authorization for disclosure
and whether the standard should vary based on the nature of the
disclosure. Also, in what situations, such as public health emergen-
cies, should disclosure take place in the absence of an individual's
permission to disclose health information or even over the individ-
ual's objection?
296 See Mark A. Rothstein, Protecting Privacy and Confidentiality in the
Nationwide Health Information Network, in PAPER KILLS: TRANSFORMING HEALTH
AND HEALTHCARE WITH INFORMATION TECHNOLOGY 17 (David Merritt ed., 2007).
297 COMM. ON THE DISPOSITION OF THE AIR FORCE HEALTH STUDY BD. ON
POPULATION HEALTH & PUB. HEALTH PRACTICE, INST. OF MED. OF THE NAT'L
ACADEMIES, DISPOSITION OF THE AIR FORCE HEALTH STUDY 115 (2006) [hereinafter
COMM. ON POPULATION HEALTH & PUB. HEALTH PRACTICE] (emphasis omitted).
298 See generally THE RIGHT TO KNOW AND THE RIGHT NOT TO KNOW (Ruth
M. Chadwick et al. eds., Avebury 1997); R. Andorno, The Right Not to Know: An
Autonomy Based Approach, 30 J. MED. ETHICS 435,435-36 (2004).
2 COMM. ON POPULATION HEALTH & PUB. HEALTH PRACTICE, supra note
297, at 115 (emphasis omitted).
300 See BARUCH A. BRODY ET AL., MEDICAL ETHICS: ANALYSIS OF THE CODES,
OPINIONS, AND STATEMENTS 161-233 (2001).
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These issues have been discussed in the literature on genetic
privacy and confidentiality, 0 1 and a threshold question is whether the
ethical analysis of epigenetic information varies from the analysis of
genetic information. Because the answer may be more a matter of
social policy than science, it may be too soon to answer inasmuch as it
is not clear what degree of stigma will attach to epigenetic data.
Although epigenetic information and genetic information have many
of the same attributes, they are not identical. For example, epigenetic
effects are environmentally induced and thus they might be viewed as
less stigmatizing because the source of the problem is not "bad
genes." They also may be reversible. On the other hand, because of
possible transgenerational effects, epigenetics may be viewed the
same as genetics. Finally, there is simply the matter of semantics.
Many policy makers and lay people will incorrectly assume that
epigenetics is just a type of genetics.
Another ethical issue to consider is whether or how to segregate
or otherwise restrict access to certain sensitive information when
health information is disclosed in electronic format for treatment or
other purposes. Several countries developing electronic health infor-
mation networks are also developing systems to isolate or mask cer-
tain data elements (e.g., clinical encounters, diagnoses) or categories
of health information (e.g., reproductive health, substance abuse, men-
tal health).30 2 Although masking certain sensitive health information
will help protect individual privacy and confidentiality, classifying
certain health information as especially sensitive might further stigma-
tize the information and result in a self-fulfilling prophecy. It remains
to be seen whether masking technologies or comparable methods will
be adopted in the United States and, if so, whether individuals will
have the option to mask genetic or epigenetic information from dis-
closure.30 3
301 See, e.g., GENETIC SECRETS: PROTECTING PRIVACY AND CONFIDENTIALITY
IN THE GENETIC ERA (Mark A. Rothstein ed., 1997); Mark A. Rothstein, Keeping Your
Genes Private, Sci. AM., Sept. 2008, at 64.
302 JOY PRITTS & KATHLEEN CONNOR, THE IMPLEMENTATION OF E-CONSENT
MECHANISMS IN THREE COUNTRIES: CANADA, ENGLAND, AND THE NETHERLANDS
(2007), available at http://ihcrp.georgetown.edu/pdfs/prittse-consent.pdf.
303 See Letter from Simon P. Cohen, Chairman, Nat'l Comm. On Vital and
Health Statistics, to the Honorable Michael 0. Leavitt, Secretary, U.S. Dept. of
Health and Human Services (Feb. 20, 2008), available at http://www.ncvhs.hhs.gov.
Masking technology applies to the disclosure of health information for treatment
purposes. "Contextual access criteria" refers to technology used to limit the disclo-
sure .of unnecessarily broad health information to third parties, such as employers and
life insurers. See Rothstein & Talbott, supra note 270, at 2884.
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C. Equitable Access to Health Care
Greater understanding of the link between environmental expo-
sures and epigenetic effects will increase the importance of exposed
individuals receiving health services for prevention, monitoring, and
treatment. Unfortunately, many of the individuals most likely to live
and work with hazardous exposures (e.g., indigent, minority, and alien
populations) are among the least likely individuals to have regular,
timely, and comprehensive access to health care.304 Thus, the issue of
access to health care for individuals exposed to substances causing or
likely to cause epigenetic harms is merely a subset of the issue of ac-
cess to health care for vulnerable populations.
In 2006, 47.0 million Americans under the age of sixty-five, 15.8
percent of the population, were estimated to be without health insur-
ance. 30 5 The percentage of uninsured for non-Hispanic white persons
was 10.8 percent, for Black persons was 19.0 percent, and for
306Hispanic persons was 34.1 percent. Since 1985, the federal
government has declared its commitment to redressing disparities in
health care access and health status for racial and ethnic minorities in
the United States.30 7 After over two decades of special emphasis on
eliminating health disparities, however, wide and persistent gaps in
health status and access to health care remain.3 °8
Numerous moral arguments have been made in support of the
notion that the richest nation on Earth should join the rest of the
industrialized world in providing access to health care for all of its
residents.30 9 One of the most powerful arguments is that access to
304 See Jack Hadley, Sicker and Poorer - The Consequences of Being Unin-
sured: A Review of the Research on the Relationship Between Health Insurance,
Medical Care Use, Health, Work, and Income, 60 MED. CARE RES. & REV. (SUPP.) 3,
38-41 (2003).
305 Press Release, U.S. Census Bureau, Household Income Rises, Poverty
Rate Declines, Number of Uninsured Up (Aug. 28, 2007), available at
www.census.gov/Press-Release/www/releases/archives/income-wealth/0l105 83.html.
306 Id,
307 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, REPORT OF THE
SECRETARY'S TASK FORCE ON BLACK & MINORITY HEALTH, 1-2 (1985), available at
http://www.omhrc.gov/assets/pdf/checked/ANDERSON.pdf.
308 See COMM. ON UNDERSTANDING & ELIMINATING RACIAL & ETHNIC
DISPARITIES IN HEALTH CARE, INST. OF MED., UNEQUAL TREATMENT: CONFRONTING
RACIAL AND ETHNIC DISPARITIES IN HEALTH CARE (Brian D. Smedley et al. eds.,
2003) (arguing for a comprehensive strategy to address disparities in health care
access). AGENCY FOR HEALTHCARE RESEARCH & QUALITY, 2005 NATIONAL
HEALTHCARE DISPARITIES REPORT (2006), available at http://ahrq.gov/
qual/nhdr05/fullreport/Index.htm.
309 See generally NORMAN DANIELS, JUST HEALTH CARE (1985) (arguing for
distributive justice in health care); 1 PRESIDENT'S COMM'N FOR THE STUDY OF ETHICAL
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health care promotes justice by preventing health problems that would
impair the functioning of healthy individuals and by restoring
unhealthy individuals to a condition comparable to the societal norm.
To be sure, health care does many things for people: it
extends life, reduces suffering, provides information and
assurance, and in other ways improves the quality of life.
Nevertheless, it has one general function of overriding impor-
tance for purposes of justice: it maintains, restores, or
compensates for the loss of (in short, protects) functioning
that is normal for a member of our species.
310
These arguments lead to the following proposition: A just society
ought to provide universal access to health care because it is a per se
good and because it is an instrumental good that facilitates a range of
opportunities for human flourishing.
Considering access to health care in light of transgenerational
epigenetic harms, which may be self-perpetuating and especially
affect vulnerable populations, the following proposition emerges: A
just society ought not permit future generations to experience the
debilitating health effects caused by current environmental exposures
when the health effects are known or knowable and the environmental
conditions are preventable or remediable.
In addition to environmental remediation, individual prevention,
monitoring, and treatment are the three main ways in which medical
intervention could ameliorate the effects of harmful environmental
exposures. The availability of preventive services is likely to be
closely related to access to health care generally. Medical monitoring
may be valuable when there are known exposures and effective treat-
ments at the preclinical or clinical stage. Medical monitoring has
been used as a remedy in toxic tort litigation,311 and it also would be
an appropriate intervention for public health agencies. It is too soon
PROBLEMS IN MED. & BIOMEDICAL & BEHAVIORAL RESEARCH, SECURING ACCESS TO
HEALTH CARE: A REPORT ON THE ETHICAL IMPLICATIONS OF DIFFERENCES IN THE
AVAILABILITY OF HEALTH SERVICES (1983) (concluding "that society has an ethical
obligation to ensure equitable access to health care for all ... [because of] the special
importance of health care: its role in relieving suffering, preventing premature death,
restoring functioning, increasing opportunity, providing information about an individ-
ual's condition, and giving evidence of mutual empathy and compassion), available
at http://www.bioethics.gov/reports/past commissions/securingaccess.pdf.
310 Norman Daniels, The Functions of Insurance and the Fairness of Genetic
Underwriting in GENETICS AND LIFE INSURANCE: MEDICAL UNDERwRmING AND
SOCIAL POLICY 130 (Mark A. Rothstein, ed. 2004).
311 James M. Garner et al., Medical Monitoring. The Evolution of a Cause of
Action, 30 ENVTL. L. REP. 10024, 10024 (2000).
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to tell what treatment modalities would be effective for epigenetic
environmental insults, but widespread adoption of treatment measures
may be politically challenging and is likely to depend on cost and
efficacy. Thus far, with regard to genetics, rather than epigenetics,
both public and private payers have been reluctant to approve pay-
ment for many clinical genetic services on the grounds that they are
experimental or not medically necessary. 12 Furthermore, the current
health care system is designed more to treat individuals when they are
ill than to provide prevention and wellness services for individuals to
maintain their good health.313
D. Intergenerational Equity
Intergenerational equity, or justice between generations, involves
"the inherent relationship that each generation has to other genera-
tions, past and future, in using the common patrimony of natural and
cultural resources of our planet. 314 According to this principle, each
generation is considered a custodian of the planet for future genera-
tions.315 Intergenerational equity requires accommodating the often-
conflicting interests of current and future generations. For example,
global climate change is caused in large part by carbon dioxide emis-
sions. The benefits of carbon dioxide emissions, in terms of current
power generation, are reaped exclusively by the current generation,
but the burdens are borne by both the current and future generations.
"The lifetime of carbon dioxide in the upper atmosphere is over 100
years, so that the full (cumulative) effects of current emissions will
not be felt until the beginning of the twenty-second century. '316 Thus,
312 See generally MAXWELL J. MEHLMAN & JEFFREY R. BOTKIN, ACCESS TO
THE GENOME: THE CHALLENGE TO EQUALITY (1998) (examining the issues surround-
ing how to distribute access to the new genetic technologies and discussing the social
and ethical problems that these technologies pose).
313 See, e.g., James F. Fries et al., Beyond Health Promotion: Reducing Need
and Demand for Medical Care, 17 HEALTH AFF. 70, 70 (1998) (arguing that reducing
the need and demand for medical services will result in better health for the individual
and lower medical costs).
314 EDITH BROWN WEISS, IN FAIRNESS TO FUTURE GENERATIONS:
INTERNATIONAL LAW, COMMON PATRIMONY, AND INTERGENERATIONAL EQUITY 21
(1989).
315 Many of the philosophical writings on intergenerational equity rely or
comment on the applicability of philosopher, John Rawls's works. Rawls argued that
any generation's expectations and responsibilities should be evaluated by using a
"veil of ignorance" as to its actual place in the sequence of generations. JOHN RAWLS,
A THEORY OF JUSTICE 136-37 (1971). See also Robin Attfield, Environmental Ethics
and Intergenerational Equity, 41 LNQUIRY 207, 218 (1998).
316 Stephen M. Gardiner, The Real Tragedy of the Commons, 30 PHIL. & PUn.
AFF. 387, 402-03 (2002). See Stephen M. Gardiner, Protecting Future Generations:
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apart from the concerns of the current generation about pollution and
climate change in the near term, to what degree should concerns about
the planetary conditions of remote, future generations influence con-
temporary decisions?
Intergenerational equity has been applied to many of the vexing
environmental issues of our time, including the disposal of nuclear
waste,317 extinction of species of plants and animals,31 8 climate
change,319 overpopulation,32 and destruction of natural resources.32'
Nevertheless, it is difficult to articulate with any precision the nature
of the duty to future generations or the process by which such consid-
322
erations are part of current policy deliberations. According to Edith
Brown Weiss, one of the leading theorists of intergenerational equity,
there are three key principles: (1) each generation should be required
to conserve the diversity of the natural and cultural resource base; (2)
each generation should be required to maintain the quality of the pla-
net so that it is passed on in no worse condition than the present gen-
eration received it; and (3) each generation should provide its mem-
bers with equitable rights of access to the legacy from past genera-
tions and should conserve this access for future generations.323
If humankind has a responsibility to future generations to refrain
from activities that cause environmental harms to the planet, including
damaging current and future generations of wildlife, then it follows
that the responsibility also extends to environmental harms that could
damage the genomes and epigenomes of future generations of
Intergenerational Buck-Passing, Theoretical Ineptitude and a Brieffor a Global Core
Precautionary Principle, HANDBOOK OF INTERGENERATIONAL JUSTICE 148-69 (Joerg
Chet Tremmel ed. 2006) (discussing the ethical and economic policy concerns sur-
rounding intergenerational buck-passing).
317 See KRISTIN SHRADER-FRECHETrE, ENVIRONMENTAL JUSTICE: CREATING
EQUALITY, RECLAIMING DEMOCRACY 95-116 (Oxford Univ. Press 2002).
318 See WEISS, supra note 314, at 193-216.
319 See Edward Page, Intergenerational Justice and Climate Change, 47 POL.
STUD. 53 (1999).
320 See PHILIP KiTCHER, THE LivEs TO COME: THE GENETIC REVOLUTION AND
HUMAN POSSIBILITIES 325 (1996).
321 See WEISS, supra note 314, at 217-55.
322 In theory, the effect of policy decisions on future generations is a concern
of all government agencies and departments. In reality, the exigencies of the present
often are given primacy over the remote interests of future generations. One innova-
tive approach was adopted by the Israeli Knesset in 2001, when it created the Com-
mission for Future Generations to protect the rights of future generations at the par-
liamentary level . See Shlomo Shoham & Nira Lamay, Commission for Future Gen-
erations in the Knesset: Lessons Learnt, in HANDBOOK OF INTERGENERATIONAL
JUSTICE 244 (Joerg Chet Tremmel ed. 2006).
323 WEISS, supra note 314, at 38.
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humans. The Universal Declaration on the Human Genome and
Human Rights provides: "The human genome underlies the funda-
mental unity of all members of the human family, as well as the
recognition of their inherent dignity and diversity. In a symbolic
sense, it is the heritage of humanity. '324  Similar reasoning would
apply to the human epigenome. Furthermore, the human genome and
epigenome are not static,325 and the relationship between changes
caused by natural biological processes and those caused by the built
environment 326 has not yet been explored to any substantial degree.
There is no widely accepted ethical argument with regard to inter-
generational equity and the human epigenome. There are however,
numerous questions to consider, including: (1) how to characterize the
nature of the duty; (2) for how many generations does an epigenetic
effect have to persist to implicate intergenerational equity; (3) how do
the severity, type, duration, and reversibility of the harm affect inter-
generational equity; (4) how should the harm's effect on individuals,
families, cultures, and humanity be assessed; (5) what effect does re-
cognition of intergenerational equity concerns and epigenetic proc-
esses have on contemporary environmental policies; and (6) how does
the existence of transgenerational epigenetic effects relate to intragen-
erational equity?
The refinement of philosophical analyses of transgenerational
environmental epigenetics will be greatly influenced by scientific
developments and the emerging understanding of biological mecha-
nisms. It is not too soon, however, to analyze the fundamental values
underlying the issues. In 1943, in his haunting and prescient mono-
graph, The Abolition of Man, C.S. Lewis wrote:
Each generation exercises power over its successors: and
each, in so far as it modifies the environment bequeathed to it
and rebels against tradition, resists and limits the power of its
predecessors. This modifies the picture which is sometimes
painted of a progressive emancipation from tradition and a
progressive control of natural processes resulting in a contin-
324 U. N. Educ., Scientific and Cultural Organization [UNESCO], Universal
Declaration on the Human Genome and Human Rights 42 (1997), available at
http://portal.unesco.org/en/ev.php-URL_ID = 13177&URLDO=DOTOPIC&URL_
SECTION=201 .html (last visited Oct. 20, 2008).
325 Fraga et al., supra note 98, at 10609.
326 The built environment refers to the combination of physical conditions that
affect humans, including their health. See generally Shobha Srivasan, Liam R.
O'Fallon, & Allen Dreary, Creating Healthy Communities, Healthy Homes, Healthy
People: Initiating a Research Agenda on the Built Environment and Public Health, 93
AM.J. PuB. HEALTH 1446 (2003).
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ual increase of human power. In reality, of course, if any one
age really attains, by eugenics and scientific education, the
power to make its descendants what it pleases, all men who
live after it are the patients of that power. They are weaker,
not stronger: for though we may have put wonderful machines
in their hands we have pre-ordained how they are to use them.
And if, as is almost certain, the age which had thus attained
maximum power over posterity were also the age most eman-
cipated from tradition, it would be engaged in reducing the
power of its predecessors almost as drastically as that of its
successors.
327
Lewis was specifically addressing the intergenerational implica-
tions of genetic enhancement or positive eugenics. Nevertheless, his
comments are also applicable to transgenerational harms to the
genome and epigenome. Any current generation - through design or
through negligence in permitting hazardous exposures - that alters the
biological inheritance of its successors has "pre-ordained" the lives of
future generations in meaningful ways. The current generation will
have weakened future generations, limited their options, and required
them to pay with their health or their lives for the environmental
misdeeds of their forebears.
E. Eugenics
The moral imperative to consider the transgenerational effects of
environmentally-induced epigenetic changes suggests the following
intergenerational genetic and epigenetic principle: Each generation
should maintain the quality of the human genome and epigenome and
pass it on in no worse condition than the present generation received
it. Although such a principle is consonant with intergenerational
equity generally and is appealing in the abstract, its application must
be carefully circumscribed or it could lead to eugenic policies.
Eugenics is the Original Sin of modem genetics. As initially for-
mulated by Francis Galton and his early followers, eugenics was a
humane, progressive, and scientific enterprise with the goal of im-
proving humanity by increasing the number of genetically well-
endowed individuals and decreasing the number of genetically
disfavored. 328 In the first third of the twentieth century, the primary
327 C. S. LEWIS, THE ABOLTON OF MAN 36 (1947).
328 See generally DANIEL J. KEVLES, IN THE NAME OF EUGENICS (1985) (ex-
plaining that Galton, an English scientist and pioneer of eugenics, intended eugenics
to be a science of improving the human population by giving more suitable races or
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governmentally-imposed method of negative eugenics was to reduce
the number of genetic "defectives" through involuntary steriliza-
tion.3 29 Although certain physical defects were considered "genetic,"
there was a significant emphasis on eliminating the "genetic defects"
of promiscuity, shiftlessness, pauperism, and other traits without a
genetic basis.330 Thus, eugenic measures were based on flawed sci-
ence, and the horrendous social policy brought about by eugenics
soon spun out of control, reaching a low point in Nazi Germany.331
"Genetically undesirable" also became equated with "socially or po-
litically undesirable" and sterilization quickly led to genocide.332 In
the United States, eugenics was epitomized by compulsory steriliza-
tion laws enacted in thirty states that resulted in the sterilization of
60,000 individuals.333
Eugenics has been thoroughly discredited since the end of World
War II as bad and often disingenuous science leading to disastrous
social policy. Yet, the repeal of laws authorizing coercive govern-
mental measures should not be equated with the complete absence of
eugenics today. Sociologist Troy Duster has written that social pres-
sures to avoid the birth of children with congenital disabilities has
increased and will continue to increase prenatal diagnosis and abor-
tion, a situation he terms "backdoor eugenics. 334 Philosopher Philip
Kitcher calls laissez-faire eugenics the current practice of limited,
optional prenatal genetic testing and utopian eugenics the availability
of these services to all citizens.335
The routine use of prenatal genetic testing and selective abortion
has been criticized on other grounds, as well. The feminist critique
argues that the ability to terminate pregnancies when the fetus has a
genetic anomaly leads to the objectification of women's procreative
bloodlines a better chance of prevailing quickly over the less suitable).
329 Id. at 96-112.
330 Id. at 46-47.
331 See generally ROBERT PROCTOR, RACIAL HYGIENE: MEDICINE UNDER THE
NAzis (1988) (arguing that previous scholars underestimated the extent to which Nazi
political initiatives arose from within the scientific community itself and the extent to
which medical scientists actively designed and administered key elements of National
Socialist racial policy).
332 See generally ALLAN CHASE, THE LEGACY OF MALTHUS: THE SOCIAL
COSTS OF THE NEW SCIENTIFIC RACISM 135 (1977).
333 J. DAVID SMITH, THE EUGENIC ASSAULT ON AMERICA: SCENES IN RED,
WHITE, AND BLACK 6 (George Mason Univ. Press 1993).
334 TROY DUSTER, BACKDOOR TO EUGENICS (1990). See also BARBARA KATZ
ROTHMAN, THE TENTATIVE PREGNANCY: PRENATAL DIAGNOSIS AND THE FUTURE OF
MOTHERHOOD (1986) (discussing prenatal diagnosis and selective abortions offering
new choices, while creating new structures and new limitations on choice).
335 KITCHER, supra note 320, at 196, 202.
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capacity.336 It also threatens to redefine motherhood by depersonaliz-
ing the experience of pregnancy and forcing women to decide what
quality of life is worth living.337 The disability rights critique argues
that abortion because of a fetal genetic anomaly is based on the
erroneous assumption that a disability precludes living a meaningful
life.338 Such attitudes also adversely affect the lives of individuals
with disabilities because their quality of life depends on educational,
employment, and similar societal opportunities. 9
In light of the controversy surrounding expanded prenatal testing
for genetic disorders, it is important to consider whether similar con-
cerns would be raised about prenatal testing for epigenetic effects. It
is possible that preconception, preimplantation, and prenatal testing
for epigenetic alterations could be developed and used as a way to
prevent the transmission of transgenerational epigenetic harms. The
prospect of adverse health conditions persisting through several gen-
erations is likely to increase the social pressure on prospective parents
to prevent the transmission of epigenetic effects. Thus, once
epigenetic testing and pregnancy avoidance or termination become an
option for prospective parents, epigenetic harms could become highly
stigmatized and the moral responsibility could shift from those entities
responsible for the environmental exposures to the parents who failed
to respond "appropriately" to the risk by preventing or terminating the
pregnancy.
340
Whenever individuals' reproductive decisions attempt to alter the
biological makeup of their offspring, the claim has been made that
they are interfering with the natural order and attempting to "play
God.",341 The notion that current generations should be resolute in not
influencing the biology of their progeny, however, is inconsistent with
the basic goals of modern medicine - quite apart from reproductive
technologies. For example, pediatric medical interventions that save
336 BARBARA KATZ ROTHMAN, RECREATING MOTHERHOOD: IDEOLOGY AND
TECHNOLOGY IN A PATRIARCHAL SOCIETY 115-16 (1989).
331 Id. at 57-58.
338 Martha A. Field, Killing "the Handicapped"-Before and After Birth, 16
HARv. WOMEN'S L.J. 79, 123-24 (1993); Erik Parens & Adrienne Asch, The Disability
Rights Critique of Prenatal Genetic Testing: Reflections and Recommendations, 29
HASTINGS CENTER REP. (SPECIAL SUPP.) 1 passim (1999).
339 See Parens & Asch, supra note 338, at 2-3.
340 See Theresa M. Marteau & Harriet Drake, Attributions for Disability: The
Influence of Genetic Screening, 40 SoC. SCI. & MED. 1127, 1130 (1994).
341 See generally TED PETERS, PLAYING GOD?: GENETIC DETERMINISM AND
HUMAN FREEDOM (1997) (recognizing widespread discomfort with genetics pre-
dicated on the intent to alter human traits and concluding that moral considerations
must guide genetic science).
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the lives of genetically impaired children have the effect of permitting
these children to reach the age of reproduction and thereby transmit
their genetic risk of impairment to future generations. The fact that
saving the lives of children afflicted with genetic disorders will bur-
den the gene pool is a morally insufficient reason to withhold bene-
ficial treatment. As the eminent population geneticist Theodosius
Dobzhansky wrote: "[I]f we enable the weak and the deformed to live
and to propagate their kinds, we face the prospect of a genetic twi-
light; but if we let them die or suffer when we can save them[,] we
face the certainty of a moral twilight.
3 42
Although concerns about eugenic implications should remain an
important consideration in evaluating policies and practices with
transgenerational genomic and epigenetic effects, the fear of eugenics
should not invariably override the obligations to future generations.
Philosopher Allen Buchanan and his colleagues have written: "Repre-
hensible as much of the eugenic program was, there is something
unobjectionable and perhaps even morally required in the part of its
motivation that sought to endow future generations with genes that
might enable their lives to go better., 343 The moral imperative to act
is even stronger when the intervention prevents the acquiring of dele-
terious transgenerational alterations and thus involves preventing their
lives from being worse.
V. CONCLUSION
Epigenetics is an exciting new avenue of scientific exploration
that already has demonstrated that certain exposures, especially during
periods of developmental vulnerability, can cause long-term harms to
exposed individuals and sometimes their progeny. Epigenetics invali-
dates the assumption that nature and nurture operate as independent
forces in influencing human development and disease.
Numerous legal and ethical issues are raised by epigenetics, espe-
cially regarding individual and societal responsibilities to prevent haz-
ardous exposures, monitor health status, and provide care. Epi-
genetics represents a new class of biological effects from harmful
exposures and adds a multigenerational dimension to environ-
mentally-caused adverse health effects. Epigenetics serves to high-
light the effects of inequality in living and working conditions, as well
342 Theodosius Dobzhansky, Man and Natural Selection, 49 AM. SCIENTIST
285,296 (1961).
343 ALLEN BUCHANAN ET AL., FROM CHANCE TO CHOICE: GENETICS AND
JUSTICE 60 (2000).
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as a range of disparities in access to health care and other societal
opportunities.
Another social challenge is that epigenetics establishes an addi-
tional basis of individual biological variation. Although many socie-
ties are only beginning to deal with the legal and ethical implications
of human genetic variation,344 epigenetics adds another layer of com-
plexity to individual variability. Epigenetics also adds another class
of sensitive health information in need of privacy protection and
another basis for possible stigmatization and discrimination. Indi-
viduals and society will be challenged to respond to these new meas-
ures of acquired human variation with policies based on the ethical
principles of respect for persons, beneficence, privacy, and justice.
Finally, epigenetics raises difficult questions about the obligations
of society to preserve the soundness of the human genome and epige-
nome for the benefit of future generations. In developing a principle
of intergenerational equity for the human genome and epigenome,
optimum social policy lies between indifference to the health burdens
of future generations and eugenic notions of manipulating heredity to
improve the human condition. The ultimate policy challenge will be
to move beyond the formulation of principles that recognize these
aims to devising feasible strategies to achieve them.
344 See Mark A. Rothstein, Legal Conceptions of Equality in the Genomic
Age, 25 L. & INEQUALITY 429 (2007) (discussing how "[t]he development of new
methods of identifying individual genomic variation can either revolutionize societal
conceptions of equality or add yet another basis for perpetuating inequality").
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